The Micro Cap Opportunity ‘Daily’

‘Before the Bell’ for Wednesday August 20, 2008

On the Radar: AESO, VION, GWDC, FRHV, HYGS,IVAN

This morning’s top Micro Cap trading ideas include, Atlantic Energy Solutions, Inc. (OTCPK: AESO), Vion Pharmaceuticals, Inc. (OTCPK: VION), Growers Direct Coffee Co. Inc. (OTCBB: GWDC), Fresh Harvest Products, Inc. (OTCBB: FRHV), Hydrogenics Corp. (NASD: HYGS), Ivanhoe Energy, Inc. (NASD: IVAN).

 
ATLANTIC ENERGY SOLUTIONS, INC. (OTCPK: AESO)                                               Up 2.94% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=AESO.PK

Atlantic Energy, founded in 1992, is a globally accredited Energy Efficiency and Resource Company and member of NAESCO (www.Naesco.org) that identifies, implements and finances energy efficiency projects designed to improve the overall efficiency of energy, water usage and renewable resources, reducing our dependency on foreign oil and diminishing our carbon footprint.

Headquartered in Saratoga Springs, NY and with a satellite office in Fairfield, NJ, Atlantic Energy Solutions assesses the energy demands and usages of municipal, corporate and industrial complexes to improve conservation and apply measures to boaster savings at the consumer level. The company incorporates the latest technologies, including wind and solar energy generation and other renewable resources focusing on energy and financial strategies to achieve comprehensive, innovative and cost-beneficial improvements.

Detailed Quote: http://finance.yahoo.com/q?s=VION.PK

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Laromustine (Cloretazine(R) (VNP40101M)), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

Recent VION News:

August 19, 2008 -  Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy

VION PHARMACEUTICALS, INC. (Pink Sheets: VION) announced today that it had entered into an agreement with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (the "HOVON") to conduct a clinical trial of laromustine (Cloretazine(R) (VNP40101M)) with standard remission-induction therapy in patients aged 18-65 with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplasia (MDS).

Alan Kessman, Chief Executive Officer, commented, "We are pleased to be working with HOVON, one of the most prestigious clinical groups in hematology oncology. We continue to believe that Cloretazine(R) will have broad utility in the treatment of hematological malignancies as both a single agent and in combination with other therapies. This trial will provide important data with regard to Cloretazine(R)'s utility in the treatment of AML when given in combination with standard remission-induction therapy for this devastating disease."

Dr. Bob Lowenberg, Chief Investigator of HOVON, said, "HOVON is focusing on the clinical development of new therapeutic options for patients with leukemia. Laromustine is a promising agent for that effort."

The trial has been designed as a Phase III study in two parts. Part A will determine the feasibility (based on safety and preliminary effectiveness) of laromustine administration at three possible dose levels in combination with cytarabine and idarubicin. Part A will also evaluate the pharmacokinetics and the clinical efficacy of the laromustine combination.

Part B is then designed to evaluate the clinical efficacy of the laromustine combination versus two cycles of cytarabine and idarubicin without laromustine with regard to clinical outcome ("event free survival"), the complete remission rate, disease free survival (DFS), risk of relapse and overall survival (OS), as well as the tolerance and toxicity, and pharmacokinetics of the combination.

The trial is expected to start this fall and will be conducted at various sites in the Netherlands, Belgium, Switzerland and Norway.

GROWERS DIRECT COFFEE CO. INC. (OTCBB: GWDC)

Up 20.00% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=GWDC.OB

Growers Direct Coffee Company Inc. ('GWDC') is a leading distributor and marketer worldwide of whole green-bean coffee produced in Papua New Guinea, Jamaica and Ethiopia. Coffee is the second most traded commodity in the world after oil in terms of dollar value of trade. The bulk of the demand comes from North America and Europe where coffee drinking is an everyday habit. However, coffee is grown in developing and less developed countries in the tropics. GWDC is bringing together the supply and demand chains of the coffee market. Through its "Tree-to-Cup" industry leading concept which it pioneered, GWDC delivers the coffee to the end-users in the developed nations to fulfill the demand and enhance its shareholders value, and at the same instance, assists to alleviate poverty in the coffee growing regions of the world by buying coffee at favorable prices to the farmers and implementing social programs to assist and improve the livelihoods of the coffee farmers.

Recent GWDC News:

August 19, 2008 - Growers Direct Provides Corporate Update and New Management

Growers Direct Coffee Company, Inc. (OTCBB: GWDC): announced today that the board of directors have appointed Mr. Mick Rynning as the new President and CEO of Growers Direct Coffee Company Inc. Interim President JD Douthitt will serve as Chairman of the board. Nepal Muhuri remains a director and interim CFO.

JD Douthitt, Chairman, stated, "Mick certainly has the credentials to lead this company and I share his vision of growth for the future. Execution is the key to success, and with Micks' proven track record of growth and management, I am confident the future of our company is in good hands."

Mick Rynning, the new President and CEO commented, "I firmly believe that our utmost success will be achieved through genuine and mutually-beneficial relationships, guided by solid strategic planning and timely tactical execution. Using a collaborative-leadership style, I intend to meet the demands of our customers, and to facilitate the success of our business partners as we forge the future together. Growers Direct Coffee Company has a business model that is uniquely positioned in today's marketplace, one that serves our coffee growers, while meeting consumer demand for best-in-class green coffee beans and artisan roasted coffees. We are just the conduit to facilitate and, as we execute, everyone in the pipeline will share in our collective success."

The new board is currently evaluating the state of our green coffee bean wholesale business, as well as our existing strategies for growth. After the review of our current strategies, affiliations and markets is complete, the board will announce its future plans regarding our "Tree-to-Cup" distribution model.

The new board has made arrangements with several sophisticated investors to provide adequate working capital for the next six months. Further long term financing strategies will be announced upon reaching agreement with the financiers.

Management is working very hard to file the currently due 10QSB, quarterly statement, for June 30, 2008 in a timely fashion.

Date and venue for the Annual General Meeting will be announced once determined by the board of Directors.

FRESH HARVEST PRODUCTS, INC. (OTCBB: FRHV)

Up 20.00% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=FRHV.OB

Fresh Harvest Products, Inc. sells, markets and distributes natural and organic food products and beverages. Under the Wings of Nature(TM) brand name, Fresh Harvest offers a line of organic snack products, which primarily include health bars, coffee bars, tortilla chips and salsa. In addition, Fresh Harvest provides a grocery product line, which includes several varieties of whole bean and ground coffees, olive oil and beverages. The Company sells its products through specialty and natural food distributors to stores, specialty supermarkets and retailers. Additionally, Fresh Harvest represents a branded line of patent pending bio-remediation products. Fresh Harvest Products, Inc. is headquartered in New York City. Additional information is available at http://www.freshharvestproducts.com.

Recent FRHV News:

August 19, 2008 - Fresh Harvest Products, Inc. Announces Update on Operations

Fresh Harvest Products, Inc. (OTC Bulletin Board: FRHV) announced today an update to its formal corporate operations and its acquisition and partnership strategy.

Strategy: Our business strategy has three key facets: (1) maximize our Wings of Nature(TM) Brand by increasing current distribution, expanding product offerings, and maximizing opportunities to reach the core consumer through trade promotional activities; (2) Utilize our Management Team and Supply Chain Operation to exclusively represent Companies/Brands that complement our current offerings; and, (3) pursue opportunities to partner and acquire assets that will enhance the Company's growth potential and increase shareholder value.

Brand Positioning: We have positioned our Brand across multiple category sectors through the delivery of high quality products that upscale shoppers can trust and support time and time again. We will deliver products with the highest quality organic/natural ingredients at competitive prices. Our objective is to be synonymous with the highest quality product in every sector. Our customers demand the very best and we will deliver it. Execution: Current product mix includes: Organic Fruit and Nut and Coffee Snack Bars; multiple blends of Organic Coffees; Organic Salsa and Organic Olive Oil(s).

Sales and Distribution: Our customer base will consist principally of Specialty and Natural Food Distributors and Key Target Retailers through distributors. We will continue our focus on the Natural Food Distribution Channel, both on specialty and retail store presence to meet consumer demand and awareness. Execution: Selling through targeted Specialty Food Distributors, with a plan to grow sales and increase distribution in fiscal 2009.

Distribution Plan: To reach specific consumer groups through targeted retail outlets utilizing Specialty Food Distributors. Growth will come from gaining the proper shelf placement, increasing distribution points and turnover, as well as the marketing support provided to each individual account. Execution: Focusing on target distributors/retailers for maximum household penetration in 2009.

New Product Initiatives: We consider research and development of new products to be a significant part of our overall philosophy. As such, we are committed to developing high-quality, all natural/organic products to improve today's lifestyle. We have and will continue to incorporate product ideas from all areas of our business to formulate new products and categories. In addition to developing new products ideas, we routinely reformulate and revise existing products based on consumer feedback for improvement and new line extensions. Execution: Currently developing Brand and Product extensions.

Third Party Brand Representation: Fresh Harvest will represent (market, sell and distribute) on an exclusive contract basis, premium complimentary natural/organic Brands through our supply chain system. The objective is to gain critical mass in operations and consumer importance through retailers/distributors utilizing previous relationships. Execution: Currently developing Brand and Product line extensions.

Acquisition & Partnership Strategy: Fresh Harvest seeks to pursue opportunities to partner and acquire assets and brands that will enhance the Company's growth potential and increase shareholder value. Fresh Harvest evaluates opportunities on a case-by-case basis and generally focuses on assets and brands that complement our existing product mix. Execution: Fresh Harvest is currently in discussions with several companies about partnerships and/or strategic alliances.

Michael J. Friedman, Founder and President, commented, "Activity continues to be positive on all of our projects in delivering our stated aim to pursue appropriate opportunities to partner and/or acquire businesses that share our approach, and whose Assets and Brands will enhance our continued growth and shareholder value. Fresh Harvest's strategy necessitates a continuation of the pursuit to deliver proper capitalization to maximize its plan."

HYDROGENICS CORP. (NASD: HYGS)

Up 16.52% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=HYGS

Hydrogenics Corporation (www.hydrogenics.com) is a globally recognized developer and provider of hydrogen generation and fuel cell products and services, serving the growing industrial and clean energy markets of today and tomorrow. Based in Mississauga, Ontario, Canada, Hydrogenics has operations in North America, Europe and Asia.

Recent HYGS News:

August 19, 2008 - Hydrogenics to Provide Fuel Cells to APC for Extended Run Back-Up Power in Data Centers

Hydrogenics Corporation (TSX: HYG)(NASDAQ: HYGS), a leading designer and manufacturer of hydrogen electrolyzers and fuel cell systems, announced today that APC by Schneider Electric, a global leader in integrated critical power and cooling services, will soon launch an extended-run back-up power system powered by Hydrogenics' HyPM XR Fuel Cell Power Modules. The Fuel Cell Extended Run (FCXR), developed in collaboration with Hydrogenics, provides uninterruptible back-up power for mission-critical applications.

The FCXR offers a lower total cost of ownership for runtime requirements greater than two hours when compared to lead acid batteries. Additionally, this solution is ideal for customers with space constraints or for companies that cannot operate a diesel generator due to noise or emissions concerns. The FCXR produces highly efficient, emission-free electrical backup power using air and stored hydrogen. Using hydrogen fuel cells lowers operating costs, increases reliability, and extends runtime duration, while reducing maintenance cost, and minimizing environmental impact.

APC's next generation Fuel Cell Extended Run product, which produces emission free electrical backup power using air and stored hydrogen, is available in 10 kW increments up to 30 kW contained in a single 19-inch rack. Developed in collaboration with Hydrogenics Corporation following the completion of a multiple unit field trial program; the second generation FCXR uses Hydrogenics' HyPM XR Fuel Cell Power Modules. Hydrogenics will be providing a turn-key critical application power systems to APC. This solution is in addition to the existing Fuel Cell Power Module agreement in place since August 2006. This solution includes power electronics, cooling, and system controls in a standard APC modular rack mount. The FCXR supports APC's 3-Phase Symmetra PX product line for uninterruptible power and adds a new dimension for extended backup time to APC's InfraStruXure architecture.

"APC's next generation fuel cell backup product represents one of the first commercial uses of fuel cell technology for data center environments," said John DiPippo, senior vice president, APC Data Center Solutions, Software and Services. "The next generation FCXR incorporates key improvements based on the successful commercial trials of our earlier fuel cell solution deployed during the past two years. We believe APC's new fuel cell product provides the right combination of power capacity and innovative hydrogen-based technology to meet market demand."

IVANHOE ENERGY, INC. (NASD: IVAN)

Up 6.12 Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=IVAN

Ivanhoe Energy is an independent international heavy oil development and production company focused on pursuing long-term growth in its reserves and production using advanced technologies, including its proprietary heavy oil upgrading process (HTL(TM)). Core operations are in Canada, the United States and China, with business development opportunities worldwide. Ivanhoe Energy trades on the NASDAQ Capital Market with the ticker symbol IVAN and on the Toronto Stock Exchange with the symbol IE.

Recent IVAN News:

August 19, 2008 - Ivanhoe Energy confirms discussions with Ecuador's national oil company on development of Pungarayacu oil field

Ivanhoe Energy Executive Chairman, President and CEO Robert Friedland confirmed today, in response to numerous enquiries and media reports, that the company, as previously disclosed, is in detailed discussions with a number of resource owners and national oil companies. The Republic of Ecuador's national oil company, PETROECUADOR, is one such company.

Mr. Friedland said that while talks are at an advanced stage toward an agreement to develop Ecuador's Block 20, known as the Pungarayacu oil field, no final agreement to embark upon the project has been entered into either by PETROECUADOR or the Ivanhoe Energy board of directors. There can be no assurance that a final agreement will be signed.

"A final agreement would require approvals by both parties and disclosure of the terms of such an agreement would be made at an appropriate time," Mr. Friedland added.

Lantis Laser Inc. (OTC: LLSR)
News Released before the Open!
 
Commentary

News out this morning from Lantis. More positive information about the capabilities of OCT as a diagnostic technology in dentistry. Read up, soak-in and do your due diligence!

The stock is holding strong since we featured it again on June 9th at $.21. Since then it hit a high of $.40 in late July. Can it make another run to $.40 and beyond? We think so. Remember, with every passing day we get closer to the launch of the company's OCT -based Dental Imaging System. Then we think its GAME OVER!

Press Release

Lantis' OCT Dental Imaging System Capable of Providing Array of Diagnostic Scanning Modalities

OCT System Can Provide Macro, Micro and Nano Imaging of Dental Tissue

August 14, 2008 9:00:00 AM

DENVILLE, N.J., Aug. 14, 2008 (PRIME NEWSWIRE) -- Lantis Laser Inc.'s (Pink Sheets:LLSR) (http://www.lantislaser.com) ongoing research into the application of Optical Coherence Tomography (OCT) imaging technology demonstrates that Lantis' OCT Dental Imaging System(tm) can provide a wide array of imaging technology and modalities that can provide fast and accurate information to aid in the diagnosis of dental disease and microstructural defects.OCT researchers have shown the ability of OCT to be used for wide-area scanning as a screening aid as well as a micro scanning device for obtaining detailed quantitative and qualitative information to aid dental professionals in making diagnostic decisions. Recent research has also shown that the use of nano particles can further enhance diagnostic ability of OCT.

Stan Baron, President & CEO of Lantis commented that, "The concept of macro imaging, micro imaging and nano imaging with OCT can provide dentists with the diagnostic aid needed to practice minimally invasive dentistry and transition to the medical model -- find disease early and treat it early. The possibilities presented by OCT technology and new research findings are very exciting and Lantis will continue to pursue relationships with research institutions where these concepts are being developed for commercial implementation."

Lantis has a strong OCT portfolio of licensed intellectual property and a strategic supply agreement for its OCT Engine with Axsun Technologies that ensures its dominance in the dental market for this next generation diagnostic imaging modality. Its OCT system provides chairside, real-time images of dental structures at a resolution of up to 10 times x-ray, and as it is light-based there is no harmful radiation. Providing more detailed information than x-ray, it is anticipated that it will likely become the dominant imaging modality in the dental office, after its introduction which is targeted for first quarter 2009.

About Lantis Laser
Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 and Phase 3 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System(tm) in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser (Pink Sheets:LLSR), visit www.lantislaser.com

‘Before the Bell’ for Tuesday August 5, 2008

On the Radar: UDHC, GFET, UVSE, NSOL, ATSI, MRVC

This morning’s top Micro Cap trading ideas include, Ulysses Diversified Holding Corp. (OTCPK: UDHC), Gulf Ethanol Corp. (OTCPK: GFET), Universal Energy Corp. (OTCBB: UVSE), Nuclear Solutions, Inc. (OTCBB: NSOL), ATS Medical, Inc. (NASD: ATSI), MRV Communications, Inc. (NASD: MRVC).

ULYSSES DIVERSIFIED HOLDING CORP. (OTCPK: UDHC)                                       Up 21.05% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=UDHC.PK

53,642,312  Restricted Shares (for one year/utilized for the SecureNetView
acquisition)

19,800,000  Common Shares  (Being Held in the Company Treasury for Pending acquisitions)

6,557,688  In the Public Float

The Board of Directors also authorized per corporate resolution that if current pending acquisitions are not executed within the next thirty (30) days that the 19,800,000 common shares being held in the company's treasury will be returned to the Transfer Agent and further reduce the authorized common shares by the same equal amount (19,800,000).

GULF ETHANOL CORP. (OTCPK: GFET)
Up 10.00 Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=GFET.PK

Gulf Ethanol is an alternative energy company focused on the development of technology for the cellulosic ethanol industry with a particular emphasis on Texas and the Gulf Coast. For more information please visit our homepage at: www.GulfEthanolCorp.com.

Recent GFET News:

August 4, 2008 -  Gulf Ethanol: It Works!

Gulf Ethanol Corporation (PINKSHEETS: GFET) announced today the first successful testing of its biomass preprocessor. The prototype unit successfully processed raw feedstocks into an extremely fine powder which will allow cellulosic ethanol producers to improve results significantly.

"We are excited to see the first successful operation of our new technology," noted Bill Carmichael, President of GFET. "We have evaluated the initial results and are now ordering some design revisions that we believe will improve the efficiency of our technology. Then we will resume further testing," he added.

The U.S. Department of Energy states that, "The initial sizing and grinding of biomass affects efficiencies and quality of all the downstream operations. New technologies and equipment are required to process biomass between the field and conversion facilities." This is the need met by our new technology.

The U.S. Department of Energy states that, "Biomass is the single renewable resource that has the potential to supplant our use of liquid transportation fuels now and help create a more stable energy future. Using our indigenous biomass resources, we can potentially fuel our cars and provide new economic opportunities across the nation." It can be converted to carbon-based fuels and chemicals, in addition to electric power. America's plan to replace 20% of gasoline with biofuels within 10 years has five steps leading from the farmer's field to the consumer's vehicle. Gulf Ethanol's feedstock pre-processing technology fits in the feedstock logistics portion of this plan which addresses transportation, costs and handling of feedstocks.

UNIVERSAL ENERGY CORP. (OTCBB: UVSE)
Up 8.70% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=UVSE.OB

Universal Energy Corp. is a publicly traded (OTC Bulletin Board: UVSE) energy company engaged in the acquisition and development of crude oil and natural gas leases in the United States. We pursue oil and gas prospects in partnership with oil and gas companies with exploration, development and production expertise. Our prospect areas consist of lands in Louisiana and Texas. Visit www.universalenergycorp.info for more details.

Recent UVSE News:

August 4, 2008 - Universal Energy Corp. Announces Increased Production at its Caviar Wells

Universal Energy Corp. (OTC Bulletin Board: UVSE), an emerging U.S. oil and gas exploration and production company, announced today that gas production has continued increasing at both Caviar #1 and Caviar #4 since initial production began in July.

"We will continue to open up the wells and increase flow as we work them into their final production levels," commented Billy Raley, Chief Executive Officer of Universal Energy Corp. Raley continued, "We are extremely pleased with the ease that these wells came online and look forward to many years of substantial production."

NUCLEAR SOLUTIONS, INC. (OTCBB: NSOL)
Up 9.09% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=NSOL.OB

Nuclear Solutions, Inc. (OTCBB: NSOL) and its subsidiaries report operations and financial results on a consolidated basis within Nuclear Solutions, Inc.'s public filings. Visit www.nuclearsolutions.com for additional information. For further information on Nuclear Solutions, Inc. please contact an authorized representative of the company. The only authorized representatives of the company are: Patrick Herda, Ken Faith, and Fred Frisco and the only authorized investor relations telephone number is (202) 580-8330 or (202) 787-1951. The company is not responsible for information transmitted by an unauthorized third party or through calls made to or from an unauthorized telephone number.

Recent NSOL News:

August 4, 2008 - Nuclear Solutions Announces New Transitional Advisory Committee Members

Nuclear Solutions, Inc. (OTCBB: NSOL) announced the appointment of Major General Lincoln Jones, III (USA Ret.), Mr. Dick Westfahl, and Mr. James McCulloch to a transitional advisory committee formed to identify and recommend candidates with a petroleum industry background for the position of President and CEO as well as other key senior management positions. In addition, this committee will make recommendations for guiding and financing the development of the company's proposed coal-to-diesel projects in Kentucky.

The transitional advisory committee reports to the Board of Directors and will provide guidance, advice, and planning assistance for the company's coal-to-diesel projects and future projects to produce synthetic diesel from coal and other feedstocks, such as oil refinery waste, petroleum coke, and scrap tires.

Each member of the transitional advisory committee, serving at the direction and discretion of the company's Board of Directors, brings energy industry expertise and experience of benefit to Nuclear Solutions.

Major General Lincoln Jones is Chairman of Worldwide Strategic Partners, Inc., an energy consulting company. He was recently appointed to the Board of Directors of Global Resource Corporation, a publicly traded company that developed microwave technology for alternative fuel use. Major Jones retired from the Army as Deputy Commanding General U.S. Army V Corps, Germany where he was Deputy to the Former Secretary of State General Colin Powell. Following his Army career, General Jones was a key executive at Enron where he served as President of Enron Power Corp. (1991-98); Vice Chairman, Enron Europe (1996-98); and President, Enron Engineering & Construction (1993-96). During that time, he developed sixteen and operated eighteen power plants throughout the world. Since retiring from Enron in 1998, he has acted as a consultant for energy, military, and geopolitical issues.

Mr. Dick Westfahl is a graduate of the U. S. Naval Academy, Annapolis, Maryland and the U.S. Naval Postgraduate School in Monterey, California with an M.S. in Oceanography. Mr. Westfahl has served as Managing Director of Enron Engineering and Construction Company (EECC) from 1997 to 2001. In this capacity he also served as Executive Vice President of National Energy Production Company (NEPCO). Prior to that position he was President of Raytheon Environmental Services Company, a subsidiary of Raytheon Engineers & Constructors Company; Regional Director of Business Development for Harding Lawson Associates, an environmental engineering and consulting firm; and Vice President-Deputy Manager of Stone & Webster Engineering Corporation. Mr. Westfahl is also an Executive Energy Consultant to Worldwide Strategic Partners since 2005, and is also currently President of Worldwide Capital Partners II, an energy consulting company. Mr. Westfahl is a retired U.S. Naval Officer with experience in various leadership positions for the U.S. Navy, including that of Commanding Officer of a nuclear submarine.

Mr. James McCulloch graduated from Tulane University in 1974 with a B.A. in Political Science, and from Tulane University School of Law in 1977 with a J.D. degree. He has been a frequent author and speaker on legal and insurance issues. Mr. McCulloch retired from Global Santa Fe Corporation, an international offshore drilling and energy services company, in December 2007 consequent with that company's merger with Transocean Corporation. At the time of his retirement he served as Senior Vice President and General Counsel, an office to which he had been appointed in 1999, and had responsibility for all legal and risk management functions of the organization. Mr. McCulloch currently also serves as an advisory board member of Sunland Construction, Inc., a privately held company engaged in the construction of natural gas pipelines and the provision of complementary services to energy customers in the U.S.

ATS MEDICAL, INC. (NASD: ATSI)
Up 4.01% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=ATSI

ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 150,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.

Recent ATSI News:

August 4, 2008 - ATS Medical Appoints New Vice President of Operations

ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced the appointment of Craig Swandal as Vice President of Operations effective August 11, 2008. Mr. Swandal was previously the Senior Vice President of Corporate Operations for Gyrus ACMI, a leader in the development and manufacture of minimally invasive surgical instruments. He has over 25 years of progressive operations management experience and is a well respected leader in the implementation of Lean and Six Sigma systems.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

In this newly created position, Mr. Swandal will be responsible for overseeing the continuous improvement and expansion of ATS Medical's best-in-class operations organization. Mr. Swandal commented, "I am excited about joining ATS Medical, particularly at a time when it is poised for significant growth. I look forward to contributing in ways that will allow us to make the most of our opportunity." Michael Dale, Chairman and Chief Executive Officer noted, "Our operations demands continue to grow through volume increases and diversification of product technology offerings. Craig's expertise and leadership will be a valuable addition to our executive management team as we strive to expand our operations capabilities in concert with anticipated growth."

MRV COMMUNICATIONS, INC. (NASD: MRVC)

Up 0.00 Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=MRVC

MRV Communications, Inc. ("MRV") is a leading provider of network equipment and services, and optical components. MRV's networking business provides equipment used by commercial customers, governments and telecommunications service providers, and includes switches, routers, physical layer products and out-of-band management products as well as specialized networking products for aerospace, defense and other applications including voice and cellular communication. MRV's optical components business provides optical communications components for metropolitan, access and Fiber-to-the-Premises applications, through its wholly owned subsidiary SourcePhotonics, Inc. MRV markets and sells its products worldwide through a variety of channels, including a dedicated direct sales force, manufacturers' representatives, value-added-resellers, distributors and systems integrators. MRV also has operations in Europe that provide network system design, integration and distribution services that include products manufactured by third-party vendors, as well as internally developed and manufactured products. Publicly traded since 1992, MRV is listed on the NASDAQ National Market under the symbol MRVC.

Recent MRVC News:

August 4, 2008 - MRV Announces New SFP Transceivers for Physical Layer SAN Test Lab Automation

MRV Communications, Inc. (Nasdaq:MRVC), a leading provider of products and services for out-of-band networking, optical transport, metro Ethernet, and fiber optic components today announced two new Serial Attached SCSI (SAS)/Serial ATA (SATA) storage interface modules for its Media Cross Connect(R) (MCC) physical layer switch, to enable "wire-once" test lab automation of storage area network test lab environments.

The protocol-specific small form-factor pluggable (SFP) modules come in 3 Gbps host-connection and drive-connection versions that are backward compatible to 1.5 Gbps. The new SAS/SATA SFPs round out MRV's test lab offerings for storage area networks (SAN), which already includes support for Fibre Channel, and Fibre Channel over Ethernet (FCoE).

The Media Cross Connect from MRV offers the ability to implement a "wire-once" physical layer switch in a test lab and manage all testing dynamically through software, rather than have to manually reconfigure test topologies. By minimizing the number of physical reconnections required for test set up, storage labs can avoid connector wear and tear and inconvenient cable length issues that are common in the SAS/SATA environment.

"Test lab automation is entering the mainstream phase of its development, which is marked by more industry players, a wider range of solutions, broad industry coalitions and wider acceptance by network equipment manufacturers," says Frost & Sullivan Industry Manager Jessy Cavazos. "MRV's announcement of its SAS/SATA solutions shows that the company is one of the leaders of this evolution because it is adding the flexibility to deliver the benefits of test lab automation to storage vendors."

"Storage networking vendors are facing a significant technology evolution that will put pressure on their test labs to increase efficiency and throughput in order to meet product shipment goals. By continuing to expand our TAP solutions, we are showing our customers that MRV will be there with them through this transition," said Noam Lotan, president and CEO of MRV Communications. "With the addition of these new SFPs, MRV continues its market leadership position by offering a complete set of interface solutions for storage industry's test lab environment."

The SFP-SATA-SAS-DR (drive version) and SFP-SATA-SAS-HT (host version) pluggable interfaces enable test lab administrators to tailor their solutions on a per port basis, connecting storage equipment of various types and protocols in a single blade or chassis, providing greater flexibility and efficiency in the storage test lab.

Availability

The SFP-SATA-SAS-DR and SFP-SATA-SAS-HT interfaces are available immediately from MRV sales representatives worldwide. More information is available at www.mrv.com/TAP.

About the MCC

The Media Cross Connect (MCC) product line from MRV is a physical layer switch that replaces the manual patch panel providing the missing link to true test automation. Using the MCC users can program connections from any port to any other port within the system. Modularly designed, the MCC is available in 72, 144 and 288 port versions. The MCC allows engineers to change test configurations with a single software command eliminating the laborious process of patching and re-patching cables dramatically simplifying the test set up and reconfiguration process. The MCC allows test equipment to be shared among test beds reducing capital expenses in the lab. Test lab automation reduces the time it takes to complete each test, allows 24/7 testing, saves engineering hours and costs and shortens the time-to-market of new products. To learn more about MRV's solutions for labs visit www.mrv.com/tap.

‘Before the Bell’ for Friday July 18, 2008

On the Radar: WSRA, LLSR, ETLC, MMTIF, VICL, NTWK

This morning’s top Micro Cap trading ideas include, Western Sierra Mining Corp. (OTCPK: WSRA), Lantis Laser, Inc. (OTCPK: LLSR), eTELCHARGE.com, Inc. (OTCBB: ETLC), Micromem Technologies, Inc. (OTCBB: MMTIF), Vical, Inc. (NASD: VICL), NetSol Technologies, Inc. (NASD: NTWK).

WESTERN SIERRA MINING CORP. (OTCPK: WSRA)                                                          Up 9.09% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=WSRA.PK

Western Sierra Mining is an aggressive gold and silver exploration and mining company focused on the historic mining districts of the Bradshaw mountains of Arizona, with additional ares of interest within Nevada and Mexico. Current projects include the SunGold, Oro Cache, and the Big Chief mining group, all of which have demonstrated high-grade mineralization with previous histories of production. Western Sierra Management's intends to continue to acquire attractive gold and silver properties in Arizona, Nevada and Mexico and to identify the character and size of our potential deposits. Long-term Company goals are to create maximum shareholder value by continuing to build a strong base of properties and advance these projects toward production or entering into joint ventures with other Junior mining companies.

Recent WSRA News:

July 17, 2008 - Western Sierra Mining Reports Valuation of Recent Arizona Mining Property Acquisition for Accounting and Reporting Purposes

Western Sierra Mining Corp. (OTC: WSRA) announced today that the Company has determined the valuation of the Company's recent acquisition of eight ore bearing properties in Arizona and recorded this amount on the Company's books for accounting and future reporting purposes.

Despite proven gold reserves in excess of 100,000 oz - a gross value of approximately $80 million based on a discounted spot gold price of $800/oz and 590,000 oz of proven silver reserves - a gross value of approximately $8 million based on a spot silver price of $12/oz - Western Sierra Mining Corp. has elected to record the recently finalized acquisition on the Company's books at the significantly discounted valuation amount of approximately $18 million equal to $.08 per common share on a fully diluted basis. Management has also elected not to include in the valuation nor record on the books the probable/indicated gold reserves in excess of 400,000 oz - a gross value of approximately $330 million based on a discounted spot gold price of $800/oz, nor the probable/indicated silver reserves in excess of 360,000 oz - a gross value of approximately $6 million based on a silver spot price of $12/oz. Management has furthermore applied various discounts in calculating the valuation in order to arrive at a conservative amount.

Michael Chaffee, CEO & President of Western Sierra Mining, commented, "Our CFO Dennis Atkins has worked diligently with management to value the acquired properties in what could only be characterized as an 'ultra conservative' manner. The full face-value of the proven reserves - even at below prevailing market prices - would be approximately $80 million or $.36 per share of book value for the proven gold reserves, approximately $320 million or $1.45 per share for the probable/indicated gold reserves and roughly $6 million or an additional $.03 per share for the probable/indicated silver reserves." He continued, "The recorded value of $18 million for these properties is testament to our financial conservatism. We believe it is in the best interests of all shareholders when management is committed to a set of rigorous financial controls and standards which to allow the market to value the Company properly, and we are firmly committed to holding to this standard as we continue to acquire and develop high-quality ore-bearing properties going forward."

Western Sierra Mining also released an up-to-date capital structure for the benefit of shareholders. As of Tuesday, July 15, 2008, the Company has 300,000,000 common shares authorized and 220,000,000 common shares issued and outstanding, of which approximately 21,000,000 are either freely trading or free trading eligible common shares in the DTC system.

LANTIS LASER, INC. (OTCPK: LLSR)
Down 6.45%Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=LLSR.PK

Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 and Phase 3 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System(tm) in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and AXSUN (exclusive).

Recent LLSR News:

July 17, 2008 - Form S-1/A Lantis Laser Inc. (10K)

eTELCHARGE.COM, INC. (OTCBB: ETLC)
Up 45.45% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=ETLC.OB

Etelcharge.com (OTCBB: ETLC), the first Web 2.0 online payment system, provides online shoppers the ability to charge approved transactions to their telephone bill. While addressing the concerns online shoppers have about identity fraud and identity theft, the Etelcharge.com payment option is also a perfect match for the millions of individuals without a credit card, or even a bank account. For more information, go to www.Etelcharge.com.

Recent ETLC News:

July 17, 2008 - Etelcharge Announces Decision of California Bankruptcy Court to Approve Etelcharge's Acquisition of Payment One

Etelcharge.com (OTCBB: ETLC), the new online way to pay(TM), today announced that the Company's acquisition of Payment One was approved by the United States Bankruptcy Court for the Northern District of California (San Jose, CA). As previously disclosed, Etelcharge entered into an agreement to acquire the outstanding equity of Payment One Corporation from The Billing Resource, which had filed for bankruptcy protection late last year. The decision of the Bankruptcy Court removes the most significant substantive condition to the closing of the transaction. It is anticipated that the additional customary closing conditions will be satisfied and the acquisition consummated within 45 days.

Pursuant to the acquisition agreement, Etelcharge will receive, by virtue of its acquisition of the Payment One equity, all of the Payment One assets, customers, nationwide telco coverage, a stellar employee base and technology developed over the past eight years.

"We are extremely pleased that the Bankruptcy Court rendered this decision," stated Rob Howe, Chairman and CEO.

"Our prospects now are extremely bright. Upon closing of the acquisition, our client list will have grown a hundred-fold over night, the prospects for new business are at our front door and we are working with the most talented people I have met during my tenure in the field of high technology. Of equal importance is the transition from a small company generating modest revenue, to a company generating $12 million in yearly revenue. The Payment One acquisition will create the foundation for the future growth of Etelcharge.com, which permits a 50 state strategy to expand our payment processing business," Howe concluded.

MICROMEM TECHNOLOGIES, INC. (OTCBB: MMTIF)
Up 27.35% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=MMTIF.OB

Micromem Technologies, Inc. (www.micromeminc.com) is focused on the development of magnetic random access memory (MRAM) and sensor technology.

Recent MMTIF News:

July 17, 2008 - Micromem Technologies Inc. - Update

Micromem Technologies Inc. (OTC BB: MMTIF) comments that in light of market conditions and the current share price, the company would like to reaffirm that all of its partnerships and commercialization initiatives are moving forward.

Listing: NASD OTC-Bulletin Board - Symbol: "MMTIF"

Shares issued: 80,345,446

SEC File No: 0-26005

VICAL, INC. (NASD: VICL)
Up 10.20% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=VICL

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

Recent VICL News:

July 17, 2008 - Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data

Vical Incorporated (Nasdaq: VICL) today announced a breakthrough with preliminary clinical trial data demonstrating that DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans. DNA vaccines are fundamentally different from conventional vaccines because they do not contain any part of the virus itself, and may offer compelling advantages in response to a pandemic outbreak because of significantly reduced development and manufacturing times.

Specifically, preliminary human safety and immunogenicity data obtained in a 100-subject Phase 1 trial of the company's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines demonstrated for the first time that DNA vaccines have achieved potentially protective levels of antibody responses (defined as hemagglutination inhibition, or HI, titers of at least 40; responses ranged from 40 to 640) in up to 67% of evaluable subjects in the higher dose cohorts. No significant safety issues were observed at any of the Vical vaccine doses tested. These results support further development of Vaxfectin(R)-formulated DNA vaccines, and could position them as potential alternatives to conventional vaccines.

"The preliminary results from this Phase 1 trial indicate for the first time that an adjuvanted DNA vaccination against H5N1 influenza is well-tolerated and can induce impressive antibody responses even against this relatively weak immunogen," said Robert B. Belshe, M.D., Dianna and J. Joseph Adorjan Endowed Professor of Infectious Diseases and Immunology, Saint Louis University School of Medicine, who was the lead external safety monitor for the study. "Successful development of a safe and effective DNA vaccine will help address the potential public health threat of pandemic influenza."

Vijay B. Samant, Vical's President and Chief Executive Officer, said, "Our preliminary Phase 1 pandemic influenza vaccine results clearly demonstrate the potential of Vaxfectin(R)-formulated DNA vaccines to achieve antibody responses in the same range as conventional vaccines. The ability to manufacture DNA vaccines in weeks rather than the months required for conventional vaccines may provide a significant advantage when dealing with an emerging infectious disease such as pandemic influenza. This trial is also important because it marks the first successful safety evaluation in humans for our Vaxfectin(R) adjuvant, which has potential applications with both DNA vaccines and conventional protein-based vaccines."

The double-blind, placebo-controlled, dose-escalation trial was conducted in approximately 100 healthy volunteers age 18 to 45 at three U.S. clinical sites. The trial was designed to assess safety and immunogenicity following intramuscular vaccination with needle and syringe or with the Biojector(R) 2000 needle-free injection system in different cohorts, and to evaluate monovalent and trivalent Vaxfectin(R)-formulated DNA vaccines at various doses. Preliminary results will be presented by Vical's Vice President of Vaccine Research, Larry R. Smith, Ph.D., at 12:25 p.m. EDT today, Thursday, July 17, at the IBC Life Sciences Next Generation Vaccines conference (National Harbor, MD - July 17-18).

In the Phase 1 trial, subjects were injected at Days 0 and 21. Primary evaluation of antibody responses was by HI antibody titers, the accepted standard correlate of protection for influenza vaccines. Responders were those subjects achieving H5 HI titers of at least 40 and achieving at least a four-fold increase from baseline HI titers. By Day 56, at least 50% and up to 67% of evaluable subjects were responders in each of the three cohorts receiving 0.5 mg or 1 mg H5 DNA doses, and there were no responders in the placebo cohort. More than 90% of the responders had sustained HI titers through the last measurement to date (Day 84). Neutralizing antibody production against H5 was demonstrated separately by microneutralization assays. For comparison, the protein-based pandemic influenza vaccine currently stockpiled by the U.S. government was approved with HI titers of 40 or more in 44% of subjects by Day 56.

Even at the lowest dose tested (0.033 mg H5 DNA), one of the six subjects was a responder by Day 56. Some subjects who received the highest H5 DNA dose were responders at Day 21 after a single vaccine injection. Preliminary analyses also showed cross-strain immune responses against a strain of H5N1 from a clade not matching the vaccine. Cross-strain protection could be important against emerging strains of pandemic influenza that may not match vaccine stockpiles.

Additional assays are ongoing to further evaluate antibody responses, breadth and magnitude of T-cell immune responses, cross-strain responses, and the relative advantages of monovalent vs. trivalent vaccines and needle vs. needle-free injection.

"These results are important to Vical for three reasons," added Mr. Samant. "First, they encourage further development of pandemic influenza DNA vaccines, for which we are currently exploring funding or partnering options. Second, they support advancement of additional Vaxfectin(R)-formulated DNA vaccines toward clinical testing. Third, they provide new incentives for potential commercial partners and collaborators to explore additional applications for our Vaxfectin(R) adjuvant for DNA vaccines as well as protein and peptide-based vaccines. We are excited by these strong preliminary antibody results, and we look forward to evaluating more detailed immunogenicity data as they become available."

DNA vaccines may offer both technical and economic advantages compared with conventional vaccine approaches. DNA vaccines encode certain proteins associated with a target pathogen, rather than using any part of the pathogen itself, and can prime the immune system as well as induce potent antibody and T-cell immune responses. DNA vaccines contain no viral particles, are non-infectious, and can be administered on a repeat basis without unwanted immune responses. Additionally, DNA vaccines have the potential to achieve proof of concept more quickly and cost-effectively than conventional vaccines, and can be manufactured using uniform methods of fermentation and purification, allowing significantly faster development and production.

Vical's monovalent vaccine contains a plasmid (a closed loop of DNA) encoding the hemagglutinin (HA) surface protein from the H5N1 influenza virus strain, A/Vietnam/1203/04. It is designed primarily to elicit antibody responses against the H5 protein but could elicit T-cell responses against H5 as well. Vical's trivalent vaccine contains the H5 plasmid plus separate plasmids encoding consensus sequences of two highly conserved influenza virus proteins: nucleoprotein (NP) and ion channel protein (M2). The trivalent vaccine is designed to elicit a combination of T-cell and antibody responses against all three proteins. Both vaccines are formulated with the company's Vaxfectin(R) adjuvant, which has demonstrated effectiveness with a variety of DNA vaccines in multiple animal models as well as dose-sparing and immune-enhancing ability in animals with a conventional seasonal influenza vaccine.

NETSOL TECHNOLOGIES, INC. (NASD: NTWK)

Up 8.17 Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=NTWK

NetSol Technologies (NASDAQ: NTWK) (DIFX: NTWK) is a worldwide provider of global business services and enterprise application solutions. NetSol uses its BestShoring(TM) practices and highly-experienced resources in analysis, development, quality assurance, and implementation to deliver high-quality, cost-effective solutions. Organized into specialized practices, these product and services offerings include portfolio management systems for the financial services industry, consulting, custom development, systems integration, and technical services for the global Healthcare, Insurance, Real Estate, and Technology markets. NetSol's commitment to quality is demonstrated by its achievement of the ISO 9001, ISO 279001, and SEI (Software Engineering Institute) CMMI (Capability Maturity Model) Level 5 assessments, a distinction shared by fewer than 100 companies worldwide. NetSol Technologies' clients include Fortune 500 manufacturers, global automakers, financial institutions, technology providers, and governmental agencies. Headquartered in Calabasas, California, NetSol Technologies has operations and offices in London, San Francisco, Sydney, Beijing, Bangkok, and Lahore.

Recent NTWK News:

July 17, 2008 - NetSol Technologies to Initiate Fiscal Year 2009 Financial Guidance on July 28

NetSol Technologies, Inc. ("NetSol") (NASDAQ: NTWK) (DIFX: NTWK), a worldwide provider of global business services and enterprise application solutions, today announced the Company will issue financial guidance for its fiscal year 2009 on July 28, 2008, reflecting the period ending June 30, 2009. The Company's financial guidance for its fiscal year 2009 will be released over the news wires and posted on the corporate Website.

Western Sierra Mining Corp. (OTC: WSRA)
Mid-day News Released!

July 17, 2008 1:58:00 PM

LAKE HAVASU CITY, Ariz.--(BUSINESS WIRE)--

Western Sierra Mining Corp. (OTC: WSRA) announced today that the Company has determined the valuation of the Company's recent acquisition of eight ore bearing properties in Arizona and recorded this amount on the Company's books for accounting and future reporting purposes.

Despite proven gold reserves in excess of 100,000 oz - a gross value of approximately $80 million based on a discounted spot gold price of $800/oz and 590,000 oz of proven silver reserves - a gross value of approximately $8 million based on a spot silver price of $12/oz - Western Sierra Mining Corp. has elected to record the recently finalized acquisition on the Company's books at the significantly discounted valuation amount of approximately $18 million equal to $.08 per common share on a fully diluted basis. Management has also elected not to include in the valuation nor record on the books the probable/indicated gold reserves in excess of 400,000 oz - a gross value of approximately $330 million based on a discounted spot gold price of $800/oz, nor the probable/indicated silver reserves in excess of 360,000 oz - a gross value of approximately $6 million based on a silver spot price of $12/oz. Management has furthermore applied various discounts in calculating the valuation in order to arrive at a conservative amount.

Michael Chaffee, CEO & President of Western Sierra Mining, commented, "Our CFO Dennis Atkins has worked diligently with management to value the acquired properties in what could only be characterized as an 'ultra conservative' manner. The full face-value of the proven reserves - even at below prevailing market prices - would be approximately $80 million or $.36 per share of book value for the proven gold reserves, approximately $320 million or $1.45 per share for the probable/indicated gold reserves and roughly $6 million or an additional $.03 per share for the probable/indicated silver reserves." He continued, "The recorded value of $18 million for these properties is testament to our financial conservatism. We believe it is in the best interests of all shareholders when management is committed to a set of rigorous financial controls and standards which to allow the market to value the Company properly, and we are firmly committed to holding to this standard as we continue to acquire and develop high-quality ore-bearing properties going forward."

Western Sierra Mining also released an up-to-date capital structure for the benefit of shareholders. As of Tuesday, July 15, 2008, the Company has 300,000,000 common shares authorized and 220,000,000 common shares issued and outstanding, of which approximately 21,000,000 are either freely trading or free trading eligible common shares in the DTC system.

About Western Sierra Mining Corp.

Western Sierra Mining is an aggressive gold and silver exploration and mining company focused on the historic mining districts of the Bradshaw mountains of Arizona, with additional ares of interest within Nevada and Mexico. Current projects include the SunGold, Oro Cache, and the Big Chief mining group, all of which have demonstrated high-grade mineralization with previous histories of production. Western Sierra Management's intends to continue to acquire attractive gold and silver properties in Arizona, Nevada and Mexico and to identify the character and size of our potential deposits. Long-term Company goals are to create maximum shareholder value by continuing to build a strong base of properties and advance these projects toward production or entering into joint ventures with other Junior mining companies.

Brass Bulls Investor Relations
Matthew Lovito
866-342-2700

‘Before the Bell’ for Wednesday July 16, 2008

On the Radar: LLSR, WNBD, LEVP, AVNU, SANM, CALP

This morning’s top Micro Cap trading ideas include, Lantis Laser, Inc. (OTCPK: LLSR), Winning Brands Corp. (OTCPK: WNBD), Lev Pharmaceuticals, Inc. (OTCBB: LEVP), Avenue Group, Inc. (OTCBB: AVNU), Sanmina-SCI Corp. (NASD: SANM), Caliper Life Sciences, Inc. (NASD: CALP).

LANTIS LASER, INC. (OTCPK: LLSR)
Down 3.33%Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=LLSR.PK

Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 and Phase 3 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System(tm) in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and AXSUN (exclusive).

Recent LLSR News:

July 15, 2008 - Lantis' OCT Dental Imaging System Featured in Report on Light-Based Diagnostic Modalities for Early Decay

Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com) issued a statement today drawing attention to a recent significant report on a leading professional dental website, www.DrBicuspid.com, highlighting the status of light-based diagnostic modalities for the early detection of decay.

Early detection of decay is an important part in the practice of minimally invasive dentistry and the "medical model" of finding disease early and treating it early with topical or chemical means to avoid surgical intervention.

Lantis' OCT Dental System is addressed in Part III.

The report was published on the internet in three parts, with the last, Part III, titled:

Beyond x-rays: Part III -- OCT brings early decay to light

http://www.drbicuspid.com/index.aspx?sec=sup&sub=img&pag=dis&ItemID=300735&wf=34

Links to Part I and Part II, which discuss currently available diagnostic products, are accessible at the end of Part III.

Lantis' OCT Dental Imaging System is based on novel, light-based bio-medical imaging technology, Optical Coherence Tomography (OCT), that enables the dentist to do diagnostic imaging, chairside and in real-time. Images can be captured at a resolution of up to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects. As the power source is light-based, unlike x-ray there is no harmful radiation.

WINNING BRANDS CORP. (OTCPK: WNBD)                                                                                  Up 20.00% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=WNBD.PK

Winning Brands' mission is to replace hazardous chemicals in widespread use with safer alternatives with an initial focus on cleaning products. Winning Brands manufactures Winning Colours® Stain Remover for consumer and commercial use as an eco-responsible alternative to traditional solvents, KIND(TM) Laundry Detergents and CLEAN1(TM) Outdoor/Indoor All Purpose Cleaner amongst other products for home and industry. For the dry cleaning industry, Winning Brands manufactures SMART(TM) Wet Cleaning Solution alternative to Perchloroethylene. SMART(TM) is used in conjunction with Professional Wet Cleaning and finishing equipment for results that make virtually all "Dry Clean Only" garments processable with water instead of solvents. The effluent from this process is recycled by the cruise ships that are increasingly using the SMART(TM) Wet Cleaning System for professional on-board garment cleaning. The SMART(TM) Wet Cleaning System is available through Solvent Free Solutions Inc. (www.SolventFree.ca). Main production for Winning Brands takes place at the Grand Rapids, Michigan facility of Surefil LLC, with some sizes being produced at Winning Brands' St. Catharine's, Ontario facility.

Recent WNBD News:

July 15, 2008 - U.S. Radio Ads Begin for Winning Brands CLEAN1(TM) Outdoor Cleaner

Winning Brands Corporation (PINKSHEETS: WNBD) (FRANKFURT: WMU) (www.WinningBrands.ca) reports that its CLEAN1™ Outdoor Cleaner which was recently listed and delivered to New York's Hackett's stores will be the target of Winning Brands' first ever U.S. radio commercials.

Q Country 102.9 based in Ogdensburg, New York broadcasts over most of the area in which the Hackett's stores are located. Choosing a country music format for the CLEAN1™ launch is a deliberate choice by Winning Brands to reach out beyond stereotypes about who might be interested in eco-responsible products. "Making smart choices is not just a trendy urban phenomenon," says Winning Brands' CEO Eric Lehner. "Eco is the new normal, and Winning Brands' eco-responsible cleaning choices are the new mainstream," he adds. "If CLEAN1™ Outdoor Cleaner and its companion eco products KIND™ Laundry and Winning Colours® Stain Remover can do well in the small towns and countryside of America, then there is no corner left in on the continent where we can't be successful." The Hackett's chain was sufficiently impressed with the benefit to its customers of having a full range of eco-responsible cleaners to mobilize all its stores in June 2008 by listing all three Winning Brands products. The CLEAN1™ radio commercials will begin July 17th and represent the first of the advertising programs that were presaged in the June 2008 Hackett's announcement about listing Winning Brands.

CLEAN1™ advertising is also breaking new ground by being targeted to men more than conventional cleaners are. Bikes, boats, BBQ's, siding and swimming pools are only a few of the big important outdoor cleaning jobs that men do without realizing that they are usually using products that are designed for indoors and kept under the kitchen sink. CLEAN1™ is recognizing the reality that men are often the ones doing these jobs and is filling the current gap in messages directed toward men that are relevant to their lifestyles -- and the women who share those interests. Winning Brands CEO Eric Lehner has become known for setting policies in the company's dealings with advertising agencies and media partners that no commercials will be condescending or demeaning of men. "I don't recognize the type of men that appear today on North American television and in movies," says Lehner. "The men out there in reality are much better than the depictions. Winning Brands will choose positive options when considering the depiction of any people -- and that includes men." The CLEAN1™ radio ad format can be heard at: http://wnbd.wikidot.com/media-gallery.

CLEAN1™ Outdoor Cleaner is manufactured by Winning Brands Corporation for consumer and commercial use as an eco-responsible alternative to cleaning the many things that get dirty outdoors. Main production takes place at the Grand Rapids, Michigan facility of Surefil LLC with certain sizes still being manufactured at Winning Brands' St. Catharines, Ontario facility. Winning Brands' full product range includes a variety of advanced cleaning solutions, such as its non-toxic SMART™ Wet Cleaning liquid alternative to Perchloroethylene used in Dry Cleaning, KIND™ Laundry Products and Winning Colours® Stain Remover -- a skin friendly alternative to conventional stain removers and solvents. The company's mission is to replace hazardous chemicals in widespread use with safer alternatives. The initial focus is on cleaning products.

LEV PHARMACEUTICALS, INC. (OTCBB: LEVP)
Up 28.65% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=LEVP.PK

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's lead product candidate, Cinryze(TM) (C1 inhibitor (human)), is being developed as a replacement therapy for hereditary angioedema (HAE), also known as C1 inhibitor deficiency. Additionally, Lev is in the process of prioritizing its C1 inhibitor development platform for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

Recent LEVP News:

July 15, 2008 - ViroPharma To Acquire Lev Pharmaceuticals

ViroPharma Incorporated (Nasdaq: VPHM) and Lev Pharmaceuticals, Inc. (OTC Bulletin Board: LEVP) today announced that the companies have signed a definitive merger agreement under which ViroPharma will acquire Lev, a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases, for $442.9 million of upfront consideration, or $2.75 per Lev share, comprised of $2.25 per share in cash and $0.50 per share in ViroPharma common stock (subject to a collar). Contingent consideration of up to $1.00 per share may be paid on achievement of certain regulatory and commercial milestones. The transaction with a potential net aggregate value of up to $617.5 million has been unanimously approved by the boards of directors of both companies. The companies expect the transaction to be completed by the end of 2008. In addition, concurrently with the execution of the merger agreement, ViroPharma purchased $20 million of Lev common stock.

The acquisition of Lev Pharmaceuticals further enhances ViroPharma's pipeline with Cinryze(TM) (C1 inhibitor (human)), which is currently under regulatory review for approval by the U.S. Food and Drug Administration as a replacement therapy for patients with hereditary angioedema (HAE), also known as C1 esterase inhibitor (C1-INH) deficiency. The use of replacement therapy in patients with C1-INH deficiency is supported by more than 35 years of clinical practice experience in Europe. C1-INH depletion is also implicated in a number of other serious inflammatory disorders.

Hereditary angioedema, or C1-INH deficiency, is a dangerous and potentially deadly inflammatory disease affecting up to 10,000 patients in the United States, caused by a genetic deficiency in an essential protein called C1 esterase inhibitor. Clinical studies have shown that prophylactic C1 inhibitor replacement therapy with Cinryze can significantly reduce the severity, duration and frequency of HAE attacks.

"This transaction is consistent with ViroPharma's stated objective of broadening our portfolio of therapies for serious life-threatening conditions in selected specialty markets," commented Vincent Milano, ViroPharma's president and chief executive officer. "Lev's orphan drug Cinryze(TM) is a life-saving therapy treating a very dangerous disease. This opportunity provides a clear strategic fit with ViroPharma: Cinryze targets a market that is addressable with modest additional infrastructure and further serves patients suffering from a disease with few treatment options. We are very pleased to add the expertise of Lev to our organization, and Cinryze to our growing portfolio of options for underserved patient populations with critical and urgent needs."

"We believe this transaction recognizes the value we have created at Lev and provides our shareholders with attractive financial terms, through the upfront payment and the opportunity to continue to share in the success of Cinryze(TM) through the ownership of ViroPharma shares and the contingent value rights," commented Judson Cooper, Lev's chairman of the board. "Leveraging the combined resources of both companies not only strengthens our C1 inhibitor development platform, but also underscores our commitment to serving patients with critical unmet medical needs."

Transaction Terms

Under the terms of the merger agreement, ViroPharma will acquire the outstanding common stock of Lev for $2.25 per share in cash and $0.50 per share in stock ("Upfront Consideration"), subject to a collar. The Upfront Consideration value could be lower or higher if the ViroPharma average common share price is lower than $10.03 or higher than $15.68 per share during the twenty trading day period prior to closing. In addition, Lev shareholders will receive the non-transferrable contractual right to two contingent payments ("CVR Payments") of $0.50 each that could deliver up to an additional $174.6 million, or $1.00 per share in cash, if the Company meets certain targets. The first CVR payment of $0.50 per share would become payable when either (i) Cinryze is approved by the FDA for acute treatment of HAE and the FDA grants orphan exclusivity for Cinryze encompassing the acute treatment of HAE to the exclusion of all other human C1 inhibitor products or, (ii) orphan exclusivity for the acute treatment of HAE has not become effective for any third party's human C1 inhibitor product for two years from the later of the date of closing and the date that orphan exclusivity for Cinryze for the prophylaxis of HAE becomes effective. The second CVR payment of $0.50 per share would become payable when Cinryze reaches at least $600 million in cumulative net product sales within 10 years of closing. The Upfront Consideration of $2.75 per share and the potential for a total value of $3.75 per share represent premiums of 49% and 103%, respectively, over Lev's closing stock price on July 14, 2008.

Closing is subject to certain conditions including approval under the Hart-Scott-Rodino Act, the approval of Lev's shareholders and other customary closing conditions. Mr. Judson Cooper, Lev's chairman of the board, and Dr. Joshua Schein, Lev's chief executive officer, respectively, and their affiliates, who collectively hold an aggregate of approximately 23% of the outstanding Lev shares, have agreed to vote their shares in favor of the transaction.

Additionally, ViroPharma agreed to make a $20 million investment in Lev, at signing, by purchasing 9,661,836 shares of Lev common stock at a 10 percent premium to the five day average closing price of Lev's shares for the period ending Friday, July 11, 2008, sold pursuant to Lev's effective registration statement on Form S-3.

J.P. Morgan Securities Inc. advised ViroPharma and DLA Piper acted as legal counsel. In addition, Piper Jaffray & Co. provided a fairness opinion to ViroPharma's board of directors. J.P. Morgan Securities Inc., as successor to Bear, Stearns & Co. Inc., advised Lev and provided a fairness opinion to Lev's board of directors. Willkie Farr & Gallagher LLP and Becker & Poliakoff, LLP acted as legal counsel to Lev.

Conference Call and Webcast Information

ViroPharma will host a live teleconference and webcast (featuring slide presentation) with senior management to discuss the strategic acquisition of Lev Pharmaceuticals on Tuesday, July 15, 2008 at 10:30 a.m. ET. Members of Lev Pharmaceuticals senior management will be available during the question and answer period. To participate in the conference call, please dial 888-299-4099 (domestic) and 302-709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

Alternatively, the live webcast of the conference call and slide presentation can be accessed via ViroPharma's website at http://www.viropharma.com. Windows Media or Real Player will be needed to access the webcast. An audio archive will be available at the same address until August 1, 2008.

Cinryze(TM) Regulatory Status

On May 2, 2008, the Blood Products Advisory Committee (BPAC) to the U.S. Food and Drug Administration (FDA) voted unanimously that there is sufficient evidence of the safety and efficacy for the approval of Cinryze for the prophylactic treatment of HAE. The data from Lev's acute treatment trial was not presented before the BPAC and is currently under active review at FDA. On May 6, 2008, Lev announced that FDA accepted for review Lev's complete response submission for Cinryze targeting an action date of October 14, 2008.

AVENUE GROUP, INC. (OTCBB: AVNU)
Up 50.00% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=AVNU.OB

Avenue Group, Inc. (OTCBB: AVNU) is engaged in the exploration and development of oil and gas reserves. Its strategy is to acquire a portfolio of oil and gas assets that include the acquisition of low risk oil and gas reserves and the generation of low risk drilling opportunities.

Avenue owns a 50% interest in the Heletz-Kokhav License and a 25% interest in the Iris License which together encompass the Heletz oilfield. The Heletz Field, Israel's only producing oil field, was discovered in 1955 and has produced over 17 million barrels of oil to date.

Recent AVNU News:

July 15, 2008 - Heletz Field Production Update

Avenue Group, Inc. (OTCBB: AVNU) ("AGI"), with its wholly owned Israel subsidiary, Avenue Energy Israel LTD. ("AEI"), is pleased to announce that it has produced over 1,300 barrels of oil from its 50% owned Heletz-Kokhav License, part of the Heletz Field in southern Israel ("Heletz"). Since restarting production on June 12, 2008, three wells have been returned to production with total daily production exceeding 60 Barrels of Oil Per Day (30 BOPD net to AEI). Three additional wells are being prepared to return to production over the next few weeks.

Levi Mochkin, AGI's Chief Executive Officer, commented:

"We are very pleased with the production rates from Heletz and the overall progress of the Heletz Field redevelopment project."

SANMINA-SCI CORP. (NASD: SANM)
Up 7.48% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=SANM

Sanmina-SCI Corporation (Nasdaq: SANM) is a leading electronics contract manufacturer serving the fastest-growing segments of the global electronics manufacturing services (EMS) market. Recognized as a technology leader, Sanmina-SCI provides end-to-end manufacturing solutions, delivering superior quality and support to large OEMs primarily in the communications, defense and aerospace, industrial and medical instrumentation, computer technology and multimedia sectors. Sanmina-SCI has facilities strategically located in key regions throughout the world. Information about Sanmina-SCI is available at http://www.sanmina-sci.com.

Recent SANM News:

July 15, 2008 - Sanmina-SCI Reaffirms Third Quarter Fiscal 2008 Guidance

Sanmina-SCI Corporation ("the Company") (Nasdaq: SANM), a leading global electronics manufacturing services (EMS) company today announced third quarter fiscal 2008 revenue from continuing operations was approximately $1.9 billion, exceeding previously provided guidance of between $1.775 to $1.875 billion. Non-GAAP diluted earnings per share for continuing operations is expected to be at the high-end of the previously provided guidance of $0.03-$0.05. Cash and cash equivalents at the end of the quarter increased by more than $100 million from the prior quarter.

The Company will release full financial results for the third quarter ended June 28, 2008 on July 23, 2008. A conference call regarding these results will be held at 5:00 PM ET (2:00 PM PT) on July 23, 2008. The conference call will be broadcast via the Internet and is accessible by logging on to the Sanmina-SCI website at http://www.sanmina-sci.com.

CALIPER LIFE SCIENCES, INC. (NASD: CALP)

Up 7.74 Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=CALP

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

Caliper and LabChip are registered trademarks of Caliper Life Sciences, Inc.

Recent CALP News:

July 15, 2008 - Caliper Life Sciences Introduces LabChip GX and GXII Microfluidic Instruments to Address Specific Needs of Proteomic and Genomic Researchers

Caliper Life Sciences, Inc. (Nasdaq: CALP) today introduced two microfluidics-based separations products, the LabChip(R) GX and LabChip GXII benchtop systems, for fast, automated, 1-D electrophoretic separations of protein, DNA, and RNA samples. The LabChip GX represents a low price entry system targeted at genomics applications, while the GXII combines both genomics and protein research applications. The LabChip GX series of instruments will be marketed by Caliper and is designed to provide scientists novel benefits including extended walk away time, higher throughput and economical plate processing ability. Caliper also provides solutions to scientists with lower throughput needs through its collaborations with Agilent and Bio-Rad.

Both systems combine Caliper's highly reproducible assay technology with advanced data analysis and visualization software. With 96-well and 384-well plate compatibility and the ability to select single wells at any location in a plate, the LabChip GX and GXII systems provide researchers with unmatched throughput, flexibility, and performance. Leveraging Caliper's patented microfluidics technology, users are able to thoroughly analyze samples in seconds instead of minutes, eliminating throughput bottlenecks and improving efficiency. The advanced data management software suite included with each system allows users to visualize results via an electropherogram or virtual gel view. Additionally it provides data in tabular form, which can then be analyzed or easily exported into a spreadsheet format.

"With applications ranging from protein therapeutics research to gene expression analysis to genotyping of transgenic mice, the LabChip GX and GXII represent an integral component of Caliper Life Sciences' overall strategy of developing products that bridge the in vitro - in vivo translational gap," said Rick Bunch, Microfluidics Product Manager, Caliper Life Sciences. "The LabChip GX and GXII provide high quality, accurate, and reproducible data that enable researchers to accelerate their discovery efforts, while saving time and money."

The new LabChip GX instrument has been designed expressly for the needs of genomics researchers for the analysis of RNA integrity for better RT-PCR and microarray gene expression data, DNA fragment analysis for sequencing applications and genotyping transgenic mice, and numerous other applications that require accurate size, concentration, or purity analysis of nucleic acid samples. A unique feature of the LabChip GX is the ability to analyze any single sample, or a subset of samples in a microtiter plate using an intuitive GUI interface. This feature enables researchers to assess RNA integrity by randomly sampling a plate or conduct "hit picking" experiments on samples of particular interest.

The LabChip GXII system, which is a complete functional replacement of the LabChip 90, provides consistent and precise analysis of both protein and nucleic acid samples. The LabChip 90 has been widely adopted by researchers developing antibody-based therapeutics and is ideally suited for quantifying size, titer, purity, and fragmentation. This automated separations platform also enables scientists to explore the effect of multiple variables in parallel -- a process which is prohibitively expensive and time-consuming using manual methods. As a direct consequence, robust methods for protein expression can be established that accelerate high throughput screening, crystallography, and analytical analyses that require large amounts of protein.

Caliper offers a broad portfolio of microfluidics chips and DNA, RNA, and protein assay kits to use with the GX and GXII systems. For additional information or to order the LabChip GX or GXII, please visit: http://www.caliperls.com/products/labchip-systems/.

July 15, 2008 9:00:00 AM

DENVILLE, N.J., July 15, 2008 (PRIME NEWSWIRE) -- Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com) issued a statement today drawing attention to a recent significant report on a leading professional dental website, www.DrBicuspid.com, highlighting the status of light-based diagnostic modalities for the early detection of decay.

Early detection of decay is an important part in the practice of minimally invasive dentistry and the "medical model" of finding disease early and treating it early with topical or chemical means to avoid surgical intervention.

Lantis' OCT Dental System is addressed in Part III.

The report was published on the internet in three parts, with the last, Part III, titled:

Beyond x-rays: Part III -- OCT brings early decay to light

http://www.drbicuspid.com/index.aspx?sec=sup&sub=img&pag=dis&ItemID=300735&wf=34

Links to Part I and Part II, which discuss currently available diagnostic products, are accessible at the end of Part III.

Lantis' OCT Dental Imaging System is based on novel, light-based bio-medical imaging technology, Optical Coherence Tomography (OCT), that enables the dentist to do diagnostic imaging, chairside and in real-time. Images can be captured at a resolution of up to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects. As the power source is light-based, unlike x-ray there is no harmful radiation.

About Lantis Laser

Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently entering Phase 3 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System(tm) in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser (Pink Sheets:LLSR), visit www.lantislaser.com

Safe Harbor: Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the safe harbors created thereby. The Company is a development stage company who continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.

CONTACT:  Lantis Laser Inc.           Stan Baron, President & CEO           (203) 300-7622           sbaron@lantislaser.com            AGORACOM Investor Relations           http://www.agoracom.com/ir/lantislaser           llsr@agoracom.com            For OCT Updates           http://www.octnews.hivefire.com 

The Micro Cap Opportunity has released a new
'Featured Pick' this morning!

Western Sierra Mining Corp.
(OTC: WSRA)
Monday, July 14th, 2008

Our newest 'Featured Pick' in a play on some of the hottest markets around, Gold & Silver Mining. Western Sierra Mining Corp, a Jr. Exploration & Mining company announced a key acquisition last week that we think will set the stock up for a big run when the numbers come out - which is supposed to happen this coming week.

Investment Considerations:

• Commodities Markets - particularly Gold & Silver - have been among the top performing markets over the past year. Expect this to continue in the wake of “tipping” inflation numbers and credit contagion-driven worldwide economic uncertainty.

• Recently acquired mining rights to 8 properties in the Arizona with “extensive mining histories and precious metal ore bodies that are geologically well documented”.

• Proven Gold reserves on acquired properties of 100,000 Oz., representing $80 Million - or $.36 per share - based on $800 Gold prices. 

• “Probable” Gold & Silver reserves total 400,000 Oz of Gold and 1,000,000 Oz. of Silver, representing a the potential for an additional $338 Million - or $1.17 per share - based on $800 Gold and $18 Silver prices.

• Production timeline for acquired properties characterized as “short-term”.

• Company recently engaged new PCAOB member Auditing firm to audit financial records, become full-reporting and list on the OTC Bulletin Board and is auditing financial records.

• A $11 Million current Market Capitalization vis-a-vis the value of the Company’s proven and probable Gold & Silver reserves and production timetable makes for a compelling risk vs. reward scenario.

• 300% short-term upside potential based on our discounting methodology.

CLICK HERE to read our coverage

OUR PICK: WSRA.PK
OUR RATING: Speculative Buy & Trade
ALERT PRICE: $.05
SHORT-TERM TARGET': $.20 (300%+ Return Potential)

Warm Wishes & Happy Trading,

~MCO Staff

P.S. Make sure you read our disclaimer on the Disclaimer Section of our website.

‘Before the Bell’ for Wednesday July 9, 2008

On the Radar: LLSR, SRSR, ECPN, DIAAF, ALTI, CTDC

This morning’s top Micro Cap trading ideas include, Lantis Laser, Inc. (OTCPK: LLSR), Sarissa Resources, Inc. (OTCPK: SRSR), El Capitan Precious Metals, Inc. (OTCBB: ECPN), Diamant Art Corp. (OTCBB: DIAAF), Altair Nanotechnologies, Inc. (NASD: ALTI), China Technology Development Group Corp. (NASD: CTDC).

LANTIS LASER, INC. (OTCPK: LLSR)
Up 8.00% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=LLSR.PK

Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 and Phase 3 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System(tm) in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and AXSUN (exclusive).

Recent LLSR News:

July 8, 2008 - Lantis Laser's OCT Dental Imaging System Will Drive the New Era of Minimally Invasive Dentistry

Fluoride and its protection against tooth decay are well documented. Its action is best on the smooth surfaces of teeth. So, what about all those pits and fissures on the biting surface where decay is most prevalent? Recently, a new generation of topical products has been developed that have the ability to remineralize enamel from the bottom up, therefore reversing that dreaded decay, but only when detected very early on.

The list of products that can be used to arrest or reverse the decay process include amorphous calcium phosphate, fluoride varnishes, fluoride rinses and disinfecting mouth rinses. For the successful implementation of these treatments, early detection of decay is essential but is difficult with present day dental diagnostics as no imaging modalities provide the level of resolution required for early detection so that minimally invasive treatment

with topical products can be prescribed. This is a barrier to the wider adoption of Minimally Invasive Dentistry (MID) and the dental profession is fully aware of this.

According to Dr. Craig Gimbel, Executive Vice President of Clinical Affairs for Lantis Laser, Inc, "The introduction of Lantis' Optical Coherence Tomography (OCT) Dental Imaging System in the first quarter of 2009 will enable dentists to non-invasively image what they never were able to do before - the microstructure of teeth at a high resolution to detect early decay, using just light."

Dr. Gimbel continued, "Even x-rays are not capable of imaging early decay in those tiny pits and fissures. OCT will drive a new generation of MID and every dental office will require an OCT System to diagnose and treat very early decay." Dr Gimbel points out "both the dentist and the patients they treat can only benefit. Early diagnosis means possibly you may avoid that dreaded dental drill."

Research studies have shown that OCT technology can provide evidence for early decay demineralization and then follow the process of remineralizing, all without the risk of radiation.

Lantis' OCT Dental Imaging System is based on novel light-based, bio-medical imaging technology, Optical Coherence Tomography, that enables the dentist to do diagnostic imaging, chairside and in real-time. As the power source is light-based, unlike x-ray there is no harmful radiation. Images can be captured at a resolution of up to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects.

SARISSA RESOURCES INC. (OTCPK: SRSR)                                               Down 11.11% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=SRSR.PK

Sarissa Resources is a junior exploration company with interests in properties with base metal, precious metal, uranium, niobium and rare-earth prospects in Northern Ontario, Canada.

Recent SRSR News:

July 8, 2008 - Sarissa Resources July Update

Sarissa Resources, Inc., ("the Company") (PINKSHEETS: SRSR) is pleased to provide this update on progress on its Nemegosenda carbonatite property in Northern Ontario.

 
--  Sarissa has completed the purchase of the 7 patented mining claims

    comprising the property, consisting of approximately 2,000 acres. Full

    title has now been transferred to Sarissa. The total purchase price was

    $380,000 of which Sarissa has paid $75,000 to date, as per the purchase

    agreement, and given back a mortgage in the amount of $305,000      repayable without interest over the period from January 30, 2009 to July 30,        2010.

--  Sarissa has staked additional claims (approximately 3,000 acres) to

    the West of its existing ground in order to secure any mineralization that

    may run under Lake Nemegosenda. Information contained in historical

    Dominion Gulf Company ("Gulf") geophysical data indicated that, "major

    values may underlie the lake."*

 
--  Space for a site office, as well as facilities for drill core work and

    storage in Chapleau have been leased.

--  The Company has completed the opening of roads to both the main D Zone

    and the East Zones.

--  Initial locations for the proposed diamond-drilling program have been

    spotted: tenders for the drilling are currently being reviewed by the

    Company.

--  Work is continuing on analysis of the potential of the East Zone.

    Prior work done in this area includes diamond drilling by Gulf, as well as

    an airborne geophysical survey of 622 line-kilometers conducted by Aerodat

    Limited in 1988.

The original drill logs from Gulf have been entered into a digital format in order to more easily work with and analyze the data; assisting in the preparation of the planned drilling program to confirm the historic results. Re-analyzing the logs has shown that some of Gulf's drilling in the D Zone was stopped while still in mineralization, indicating the deposit is open to depth.

Some historic intersects from the main D Zone are reported as follows:

Nemegosenda - D Zone *

                  Sample     Weighted

Hole Number       Length      Average

                ----------- -----------

                   Feet       % Nb2O5

                ----------- -----------

DDH-208-56-26           253        0.60

                ----------- -----------

DDH-208-56-47           209        0.45

                ----------- -----------

DDH-208-56-49           518        0.60

                ----------- -----------

DDH-208-56-51           339        0.63

                ----------- -----------

DDH-208-56-52           447        0.66

                ----------- -----------

DDH-208-56-53           259        0.57

                ----------- -----------

DDH-208-56-54            50        0.42

                ----------- -----------

DDH-208-56-55           500        0.53

                ----------- -----------

DDH-208-56-56           200        0.57

                ----------- -----------

DDH-208-56-57           195        0.51

                ----------- -----------

DDH-208-56-58           202        0.50

                ----------- -----------

DDH-208-56-59           325        0.50

                ----------- -----------

DDH-208-56-60           298        0.42

                ----------- -----------

DDH-208-56-62           424        0.56

                ----------- -----------

DDH-208-56-64           401        0.57

                ----------- -----------

DDH-208-56-65           108        0.54

                ----------- -----------

DDH-208-56-66           109        0.68

                ----------- -----------

In addition, Gulf internal correspondence on the East Zones, dated January 5, 1972, reported that drilling of 7960 feet in 19 holes has indicated, "Nb2O5 mineralization similar to Zone D... In addition to niobium, the Eastern Ore Area contains rare earths such as cerium, yttrium, lanthanum and neodymium... all rare-earth elements are present in significant amounts in the East Ore Area except promethium and lutetium." The correspondence continues to say; "Initial assay results from material collected in 1971 indicate the presence of a major ore body (bodies) of light rare-earths and columbium [niobium] in the East Ore Area with the possibility of heavy rare-earth elements as a by-product."

In a "Report on the Geology and NB, Y, REE Potential of the East Zone, Nemegosenda Lake Alkaline Complex" by the consulting geological services company, Beaty Geological Ltd. of Vancouver, BC, it was reported that, "samples collected from outcrop in the 'East Zone' have quantitative analyses, with values of 0.29% yttrium oxide, 1.61% cerium oxide, 0.76% lanthanum oxide 0.62% neodymium oxide, and 440 ppm europium reported from one [sample]."

Dr. Cam Cheriton, a director of Sarissa, is a "qualified person" within the meaning of National Instrument 43-101 and has read and is responsible for the technical information contained in this news release.

* These reported resources are historical in nature and, therefore, not compliant with National Instrument 43-101 reporting standards; however they are considered material to the prospectivity of the Nemegosenda Project. A "qualified person," as defined under NI-43-101, has not done sufficient work to comment on the relevance or reliability of these historical estimates. The company is not treating the historical estimate as, nor can the historical estimates be relied upon as, current mineral resources or reserves. Sarissa currently does not have access to more recent estimates or data relating to the Lake Nemegosenda property, except as outlined in this and previous news releases.

EL CAPITAN PRECIOUS METALS, INC. (OTCBB: ECPN)

Up 35.71% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=ECPN.PK

El Capitan Precious Metals, Inc. is a U.S.-based mineral exploration company whose primary asset is a 40% interest in the El Capitan precious metals project, located in Lincoln County, New Mexico. The Company's stock trades on the Over-the-Counter Bulletin Board under the symbol ECPN.

Recent ECPN News:

July 8, 2008 - El Capitan Precious Metals, Inc. Reports Encouraging Metallurgical Results

El Capitan Precious Metals, Inc. (OTCBB:ECPN) has received encouraging reports from one of the Company's ongoing metallurgical initiatives; tin fusion followed by electrolytic parting. Preliminary results indicate that the composite samples tested contain gold, silver and platinum group metal (PGM) grades comparable to the caustic fusion values used to prepare the Company's El Capitan deposit resource evaluation. The results were significant enough to justify the continuation of two larger tin fusion tests that were initiated in late June, and are expected to provide preliminary results in three to six weeks.

Kenneth P. Pavlich, President & C.E.O., noted, "As reported in February, standard fire assay techniques typically used for gold & silver deposits similar to those found in northern Nevada have not provided the appropriate consistency and reliability necessary for demonstrating the commercial in-ground and extractable value of the El Capitan material. We have observed that the unique poly-metallic nature of the El Capitan deposit results in significant slag and/or cupellation losses when using lead collection fire assay, and the oxide nature of the deposit does not lend itself well to the application of nickel sulfide fire assays techniques typically used in sulfide PGM deposits."

"Several years ago, ECPN investigated fusion / electrolytic parting techniques with interesting, although inconsistent, results. Since then, one of our R&D partners, Wendell & Company, who at the time had been commissioned to replicate those results, continued investigations into other fusion / electrolytic parting techniques that have been reported upon in technical publications. Armed with their knowledge of techniques that have shown success with oxide, poly-metallic, precious metals deposits, they tested several metal collection fusions, followed by electrolytic parting. Their work has shown success with another client, and they have continued to optimize these techniques."

"In May, while performing other work for ECPN, they described their findings and encouraged the Company to consider testing the process. Preliminary fusion tests were performed on several composite samples using lead and tin as a precious metals collector, followed by electrolytic parting of the collector metal from the precious metals. In this process, the precious metals become concentrated in the resultant 'anode mud'. This anode mud has been subsequently examined using both atomic absorption (AA) and Scanning Electron Microscope (SEM) techniques. We are encouraged with the results from the initial tests, and are anxiously awaiting the preliminary results from the larger sample later this summer. While other metallurgical initiatives remain ongoing, this technique currently appears to hold the most promise for establishing the commercial value of the El Capitan deposit in a timely manner."

Mr. Pavlich concluded, "While we recognize that this approach represents a cumbersome assay procedure, we are pleased that the anode mud is, essentially, a saleable product. Importantly, we believe that the process could be scaled-up using existing equipment and technology common in the base metal minerals industry. While there is clearly much optimization work ahead, the knowledge that we are working with a technologically viable extraction procedure is quite exciting."

DIAMANT ART CORP. (OTCBB: DIAAF)

Up 33.33% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=DIAAF.OB

Diamant Art Corporation (OTCBB: DIAAF), through its wholly owned subsidiary Diamant Film Inc. (www.diamantfilm.com) and Bio-Plastics Film Inc., is the world's first plasticizer-free and the first food wrap film that is environmentally friendly and recyclable. Diamant's Bio-Products contain Totally Degradable Plastic Additive. Unlike other plastic, once biodegrading is complete, all that remains is carbon dioxide, water and biomass, all of which are part of the normal bio-cycle. Diamant(TM) Film has received the ECO logo certified by the Environmental Choice(TM) Program. The Environmental Choice(TM) Program is North America's leading benchmark of environmentally responsible products and services and the sole supplier of The Nor-X additive in North America.

Recent DIAAF News:

July 8, 2008 - Diamant Art Corporation Announces the Retaining of 3R Logic Ltd., an Independent Sales Agency, to Meet Swiftly Escalating Demand

Diamant Art Corporation (OTCBB: DIAAF) is pleased to announce that the Company is currently launching their Nationwide expansion strategy into the Eco Friendly marketplace under the representation of 3R Logic Ltd, an Environmentally friendly Sales Agency representing over 40 years experience in the Packaging industry.

Independent Mill Rep Gerald Duncan will be the appointed Key Executive to represent Diamant as the Nationwide Sales Director. Equipped with over four decades of experience in the packaging industry, his key responsibilities will consist of creating relationships with prospective businesses and plastics manufacturers, in an effort to create a profitable marketing segment for the company.

Now that the Company has achieved a robust new level of available inventory, the Company is taking steps toward being an industry leader in the Biodegradable solutions sector. The Company expects that with this retaining of 3R Logic Ltd., in addition to the considerable availability of the product, these conjoining factors play a leading role in the company's rise to becoming a leader in the industry.

About 3R Logic Ltd: 3R Logic Ltd was Incorporated in April of 1997, with an intended focus to Source and Market Environmentally friendly packaging products. The founders have over 40 years experience in the Packaging industry, having distributed numerous plastic products such as Bubble Wrap, Stretch Film/Restaurant Supplies; trays, Pizza Boxes, Plastic Knives and Forks. 3R Logic has represented the following companies in the distribution of theirs products;

Current Clients

    ITW Gale Wrap

    Crayex Corporation

    Celcor Limited

    Terdun Materials

    Southern States Packaging

    Fresh Pak Corporation

    Superior Packaging Inc

    Amerigreen Industries

    Pratt Industries

    Procter & Gamble

    Coca Cola

    Molson's

    Labatt

    Cabot Corporation

    Danone Water

    Nestlé

    Shur Gain (Nutreco)

About Bio-Plastics Film Inc.: Bio-Plastics Film Inc. is a fully integrated Company committed to providing Green Environmental products and technology to the world marketplace. Diamant Film Inc. provides a full range of Bio-Plastic additives, allowing Polyolefins and Plastics of all types to become fully biodegradable. Diamant Plastics is unique in the Marketplace as the only Biodegradable additive company to manufacture and distribute their own Biodegradable Shrink Films, Cling Films, Pallet Wrap and Plastic sheeting through their wholly owned subsidiary Bio Plastics Inc.

 
ALTAIR NANOTECHNOLOGIES, INC. (NASD: ALTI)
Up 33.79% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=ALTI

Altairnano is an innovator and supplier of advanced novel, ceramic nanomaterials. A seasoned management team with substantial experience in commercializing innovative, disruptive technologies, complements Altairnano's leading edge scientists. The company has developed nanomaterials for the alternative energy, life sciences and performance materials markets based on its proprietary manufacturing process. This process also provides the foundation for its innovative AHP pigment process. Altairnano is a leading manufacturer of advanced battery pack systems, which are used in stationary power applications, and electric and hybrid-electric vehicles. For more information visit: www.altairnano.com.

Recent ALTI News:

July 8, 2008 - Altair Nanotechnologies Announces Successful Grid Interconnection and Operation of Two-Megawatt Battery System

Altair Nanotechnologies Inc. (NASDAQ: ALTI), a leading manufacturer of safe, high-performance lithium-titanate battery and energy storage products, announced today the successful completion of a demonstration and validation program for a two-megawatt 500 kilowatt-hour battery system purchased by AES Corporation (NYSE: AES).

The program was developed and validated by KEMA, Inc. and executed by AES personnel and subcontractors. KEMA's testing showed the battery system successfully met the program's milestones, which was conducted to demonstrate the applicability of Altair's large platform technology to frequency regulation, a key service currently provided by power plants to the electric grid. This demonstration also suggests that the technology could be used for several other utility applications.

"The positive AES results validate the immense opportunities in the utility sector," said Terry Copeland, President and CEO for Altair Nanotechnologies. "Our patented lithium titanate battery technology represents a significant advancement in frequency regulation and can provide utilities and generating companies with a valuable tool and resource in the growing challenge of grid management."

"We are pleased with the results of the Altairnano units. This two megawatt validation project is one of the final steps in our move towards commercial deployment of grid-scale energy storage," said Chris Shelton, Director of Energy Storage Development at AES. "Fast-responding, high-efficiency energy storage systems such as these will create a more resilient grid and allow for increased use of variable generating sources such as wind and solar."

The two-megawatt battery system was installed and operated at a substation owned by Indianapolis Power & Light (IPL), an AES company. The system contained two one-megawatt battery storage units each consisting of one Altairnano 250 kilowatt-hour lithium titanate battery stack, AC-to-DC power conversion system, HVAC units, a control system and transformers to connect to the IPL grid. During the validation exercise the capacity of each unit was tested by repeatedly charging and discharging at one megawatt for 15 minutes. In a second test, two megawatts of power from each of the units were used to show the capability of paralleling two separate systems. Additional testing included simulated frequency regulation, which involved switching the units from charge to discharge at up to one megawatt of power every four seconds for several hours. The KEMA summary report will be available on Altair's website, www.altairnano.com and on the KEMA website at www.kema.com.

In August 2007 AES Corporation and Altair Nanotechnologies announced a joint development and equipment purchase agreement. Under the terms of the agreement, the companies will develop a suite of energy storage solutions. This first solution is a modular unit designed to deliver in excess of one megawatt of power and 250 kilowatt-hours of energy per unit. Multiple units can be linked together in systems to provide both more power and more energy storage.

Altair and AES are working together toward utilization of these systems to provide more efficient management of energy quality, frequency control, and real-time energy fluctuations in milliseconds at grid level. The battery systems' extended cycle-life, high-efficiency, and power profile for the continuous delivery of pulses of plus or minus one megawatt to the grid differentiate Altair's battery storage system from other potential solutions in the marketplace.

CHINA TECHNOLOGY DEVELOPMENT GROUP CORP. (NASD: CTDC)

Up 20.15 Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=CTDC

CTDC is a provider of solar energy products and solutions in China focusing on a-Si thin-film technology. CTDC's ultimate principal shareholder is China Merchants Group ( http://www.cmhk.com ), one of the biggest state-owned conglomerates in China. For more information about CTDC, please visit our website at http://www.chinactdc.com

Recent CTDC News:

July 8, 2008 - CTDC Signs LOI to Co-Develop the Xiamen Bay Solar City

China Technology Development Group Corporation (Nasdaq: CTDC; "CTDC" or "the Company"), a provider of solar energy products and solutions in China focusing on a-Si thin-film technology, today announced that the Company signed a Letter of Intent ("LOI") with China Merchants Zhangzhou Development Zone ("CMZD"), to co-develop the Xiamen Bay Solar City during the Solar City's grand opening ceremony held in CMZD on June 28th.

The LOI was signed by Alan Li, Chairman and CEO of CTDC and Mr. Bin Wu, General Manager of the CMZD. Under the terms of the letter, 100 acres within the CMZD have been designated for the construction of the solar city project, which will incorporate CTDC's current SnO2 production lines and its future BIPV applications projects. In addition, CMZD agreed to commit in providing ongoing cooperation for CTDC to further develop its a-Si solar thin-film technology.

"We are delighted to receive this assurance of continued strong cooperation and mutual support between China Merchants Zhangzhou Development Zone and CTDC," commented by Alan Li. "The commitment will provide opportunities for us to further develop and expand the SnO2 production facility within the Xiamen Bay Solar City. In addition, it will allow us to better execute our expansion strategy in the broader downstream BIPV market."

Moreover, over one hundred guests attended the ceremony, including government officials, financial analysts and solar industry leaders from Mainland China, Taiwan, Hong Kong and the United States. Among the industry leaders who joined the opening celebration was Mr. William P. Nesmith, Senior Energy Advisor of the National Association of State Energy Officials (NASEO) in the United States. Mr. Nesmith commented, "The Xiamen Bay Solar City development incorporates the global trends of a rapidly growing renewable energy sector, and demonstrates the emphasis that the PRC local government's stronger support of the renewable energy sector, while highlighting the capabilities and social responsibility of Chinese solar energy enterprises."

July 8, 2008 9:00:00 AM

DENVILLE, N.J., July 8, 2008 (PRIME NEWSWIRE) -- Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com),

About Lantis Laser

Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently entering Phase 3 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System(tm) in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser (Pink Sheets:LLSR), visit www.lantislaser.com

Safe Harbor: Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the safe harbors created thereby. The Company is a development stage company who continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.

CONTACT:  Lantis Laser Inc.           
Stan Baron, President & CEO 
(203) 300-7622
sbaron@lantislaser.com

AGORACOM Investor Relations
http://www.agoracom.com/ir/lantislaser
llsr@agoracom.com 

For OCT Updates 
http://www.octnews.hivefire.com

On the Radar: GTEM,BIHC, CROE, TCGD, ZIXI, FNSR

This morning's top Micro Cap trading ideas include, Global Tel Communications Corp. (OTCPK: GTEM), BIH Corp. (OTCPK: BIHC), CoroWare, Inc. (OTCBB: CROE), TraceGuard Technologies, Inc. (OTCBB: TCGD), Zix Corp. (NASD: ZIXI), Finisar Corporation. (NASD: FNSR).

GLOBAL TEL COMMUNICATIONS CORP. (OTCPK: GTEM)

Up 31.43% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=GTEM.PK

GlobeTel Communications Corp. develops and provides an integrated suite of aerospace communications products and services, leveraging its relationships with leaders in UAV (Unmanned Aerial Vehicle) technologies. Sanswire Corp. is focused on the design and construction of various aerial vehicles capable of carrying payloads that provide persistent surveillance and security solutions at various altitudes.

Recent GTEM News:

July 1, 2008 - Stratospheric Flight Technology Showcased, Demonstrated At Stuttgart Conference Hosted by Sanswire -TAO Corp.

GlobeTel Communications Corp. (Pink Sheets:GTEM) today announced that Sanswire-TAO Corp., the joint venture owned by its Sanswire Corp. subsidiary and TAO Technologies GmbH, showcased the Company's high altitude unmanned aerial vehicles (UAV) development capabilities in Stuttgart. The demonstrations included the unveiling of new technological advancements within the company's high altitude long endurance (HALE) program and detailed strategies, leading to demonstrations of facilities, components and systems, and live flights of various aerial platforms. Key accomplishments of the conference included:

    * Flight demonstrations of the SAS-51 airship with a live video

      surveillance package, lightweight compact autonomously controlled

      vehicles, and multiple "AirChain" prototypes, illustrating the

      inherent flight properties of the segmented cell design in flight

    * Theoretical presentations of the company's patented "AirChain"

      segmented cell airship design in comparison to the flawed

      characteristics of non segmented, rigid designs

    * Introduction of various proprietary software systems, including

      the advanced modeling and design language developed by TAO to

      theoretically evaluate lighter than air (LTA) vehicles using

      numerous interchangeable characteristics such as payload,

      duration and altitude. These systems use the data gathered from

      thousands of test flights to customize an airship with specific

      capabilities for wind speed, payload capacity and endurance

    * Presentation of the company's flight strategies, including ground

      control, launch sequences and return strategy, utilizing a

      proprietary autonomously controlled parachute payload return

      system to provide safe return of vehicle and payload under

      normal and extreme conditions

    * Showing the proprietary subsystems, including its autonomous

      flight control software and state of the art propulsion system,

      designed to immediately provide persistent service for missions

      requiring station keeping at mid altitudes utilizing a rotation

      of vehicles in approximately one week cycles.

    * Tours of facilities, including laboratories, testing and

      construction facilities, which included the equipment and

      resources utilized in the fabrication of electronics, components

      and materials used in the construction of airship platforms

Jonathan Leinwand, Chief Executive Officer of GlobeTel Communications, stated, "We would like to thank Dr. Kroplin and his team for this incredibly informative conference. We believe the demonstrations were an overwhelming success and an affirmation of our confidence in the Sanswire-TAO development programs. Our guests were able to see the depth of knowledge that has been developed by TAO during its 14 years of airship development. We have shown our capabilities to provide the next generation of lighter than air unmanned aerial vehicle platforms to our partners and customers."

About Sanswire-TAO Corp.

Sanswire-TAO exclusively owns and markets all the technology and intellectual property associated with TAO's lighter than air (LTA) unmanned aerial vehicles (UAV), including the Stratellite(tm) high-altitude airships, the SAS-51 low-altitude airships, the mid-altitude SkySat airship category and the PADDS Precision Air Drop Delivery System in the US, Canada and Mexico. Sanswire-TAO Corp. is jointly owned by TAO Technologies GmbH and Sanswire Corp., a subsidiary of GlobeTel Communications Corp. For more information, visit www.sanswire-tao.com.

BIH CORP. (OTCPK: BIHC)
Up 74.11% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=BIHC.PK

BIH Corporation operations consists of the recently acquired wholly owned subsidiary Baron International, a 25-year-old specialty beverage systems equipment sales, service supplier, walk-in refrigeration, AC systems, restaurant design & build out and much more enterprise.

Recent BIHC News:

July 1, 2008 - TAKK Systems, Inc. Announces That Baron International Will Install All the BeerMON Systems Nationally

TAKK Systems, Inc. today announced that they have reached an agreement with Baron International (PINKSHEETS: BIHC) where Baron and its affiliates will install all of TAKK's BeerMON systems nationally.

This agreement will give TAKK Systems the ability to quickly install and service their customers and locations all over the United States.

About TAKK Systems, Inc.

TAKK Systems is the developer of BeerMON, an easy-to-use draft beer monitoring system without all the complicated software installs and computer setups. We understand that not everyone is a computer tech. We setup the system and maintain it on an easy-to-use website. Our system stops slippage by alerting clients of unaccounted pours as they occur in real time, helping our clients to become more profitable. Please visit us at www.takksystems.com.

COROWARE, INC. (OTCBB: CROE)
Up 20.00% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=CROE.OB

CoroWare Technologies, a subsidiary of CoroWare, Inc. (OTCBB: CROE), is a systems and mobile robotics integrator that delivers high-value services and innovative solutions to maximize technology investments and achieve customers' goals. CoroWare has a depth of knowledge and breadth of experience in developing software and solutions for mobile service robotics and business automation through products that include the CoroBot product line. For more information, please visit http://www.coroware.com.

Recent CROE News:

July 1, 2008 - CoroWare Announces Availability and Pricing of CoroWare ClassPack for Microsoft Robotics Studio

CoroWare Technologies, a wholly owned subsidiary of CoroWare, Inc. (OTCBB: CROE), announced pricing and availability of CoroWare ClassPack for Microsoft Robotics Studio (CoroWare ClassPack), a simulation software package that complements its CoroBot mobile robot product line.

Combined with CoroWare's CoroBot, ClassPack is an affordable and effective robotics solution for teaching and research. By using the CoroWare ClassPack services, students can write robotics applications that will run both in simulation and on a real CoroBot. ClassPack features a classroom environment which allows the robot to encounter common objects found in an office or classroom. An easy-to-use control panel interface allows for remote control of the CoroBot.

"Simulation is the perfect tool for educators and researchers since they can realistically model any environment without the pains and costs involved with creating that environment," said Sara Morgan, CoroWare Robotic Software Engineer, and author of "Programming Microsoft Robotics Studio." "Students and researchers can experiment with a lower-cost version of CoroBot in the simulation environment, and then run their application on a real CoroBot in the classroom or lab."

CoroWare plans to make CoroWare ClassPack generally available at the end of June 2008 with two licensing options. An unlimited license will allow ClassPack to be installed and run on a single computer with no expiration date for a suggested retail price of $299 USD. A limited license will allow ClassPack to be installed on a single computer for the duration of a class term for a suggested retail price of $99 USD. Volume discounts for CoroWare ClassPack pricing will be available upon request for educational institutions.

"We are excited to see CoroWare continue to build upon its expertise in robotics simulation and its line of products," said Dan Kara, industry analyst and president of Robotics Trends. "We believe the introduction of new products to the market like CoroWare ClassPack will further drive the adoption of robotics at universities and colleges worldwide."

The latest version of the CoroWare ClassPack for Microsoft Robotics Studio can be downloaded from www.corobot.net. For more information on all of CoroWare's products and services, visit www.coroware.com.

TRACEGUARD TECHNOLOGIES, INC. (OTCBB: TCGD)
Up 25.81% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=TCGD.OB

TraceGuard Technologies develops innovative security technologies and solutions for enabling explosives detection through automated trace extraction. By advancing the efficacy and efficiency of trace collection, TraceGuard's product suite offers dramatic improvement in explosives detection capabilities for aviation and homeland security authorities worldwide.

TraceGuard is a US public company traded on the Over-The-Counter Bulletin Board (OTC BB:TCGD). TraceGuard maintains a Research and Development Center in Tel Aviv, Israel and has a Sales office in New York. For additional information on TraceGuard, please contact TraceGuard at 1 866-401-5969 or visit www.traceguard.com.

Recent TCGD News:      

July 1, 2008 - CompactSafe(TM) System Certified as an Explosive Detection System at International Border Crossings

TraceGuard Technologies Inc. (OTC BB:TCGD), a developer of technologies and solutions for improving automated explosives detection, announced today that the Israeli Security Agency (ISA) has completed extensive testing of the CompactSafe(TM) system and has certified it to replace manual processes of explosive detection at international border crossings.

CompactSafe(TM) inspects complex items at passenger and baggage screening checkpoints, and works in conjunction with security equipment currently in use to improve accuracy and efficiency in detecting explosives. The system is specifically designed to extract traces of explosives from items such as laptops, electronic devices, shoes and similar size items that are carried in carry-on luggage, and can also be adapted to improve detection for narcotics and other hazardous materials.

Automating inspection processes is a key goal of security and regulatory agencies. The automatic CompactSafe(TM) system improves the quality of the inspection process, while providing better service to the public and reduces overall operating costs.

The CompactSafe(TM) system has already been field tested at Ben Gurion Airport with the cooperation and participation of the Israel Airport Authority, as well as at the Western Wall in Jerusalem, with the cooperation of the Israeli police force.

"TraceGuard is very proud to have completed the ISA certification process. The ISA is known to be one of the most demanding certifying agency worldwide. We believe that CompactSafe(TM) offers a unique solution to improving explosives detection, one of the critical challenges in border crossing and in public events. This approval allows us to start sales of the CompactSafe(TM) system in Israel and other countries." said Avi Kostelitz, CEO of TraceGuard.

ZIX CORP. (NASD:  ZIXI)                                                                                           Up 10.79% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=ZIXI

ZixCorp is the leading provider of easy-to-use-and-deploy email encryption and e-prescribing services that Connect entities with their customers and partners to Protect and Deliver sensitive information in the healthcare, finance, insurance and government industries. ZixCorp's hosted Email Encryption Service provides an easy and cost-effective way to ensure customer privacy and regulatory compliance for corporate email. Its PocketScript(R) e-prescribing service saves lives and saves money by automating the prescription process between payors, doctors and pharmacies. For more information, visit http://www.zixcorp.com.

Recent ZIXI News:

July 1, 2008 - New Jersey Hospital Association Renews Exclusive Agreement With Zix Corporation After Successful Five Year Alliance

Zix Corporation (ZixCorp(R)), (Nasdaq: ZIXI), the leader in hosted services for email encryption and e-prescribing, today announced that New Jersey Hospital Association (NJHA) has renewed its marketing agreement with ZixCorp as the exclusive, preferred provider of Email Encryption Service for its association. NJHA supports more than 100 hospitals and health systems in the state of New Jersey.

ZixCorp and NJHA originally signed an exclusive marketing agreement in 2003 and currently there are more than 57 hospitals in New Jersey that secure their email with ZixCorp. NJHA is also a ZixCorp customer and has been using the Company's Email Encryption Service for five years to communicate seamlessly with its association members and business partners. As a ZixCorp customer, NJHA instantly plugged into ZixDirectory(TM), the largest email encryption directory in the world with more than 11 million members, interconnecting a network of communities that use ZixCorp's Email Encryption Service to send and receive secure email. ZixDirectory connects all ZixCorp customers for seamless, transparent, and secure email. The ZixDirectory has now grown to include more than 1,000 hospitals, more than 30 Blues organizations, more than 600 financial institutions, the federal banking regulators, 19 state banking regulatory agencies and a growing number of federal, state and county governments.

"ZixCorp has proven itself as the dominant healthcare encryption service provider year after year and by all accounts is the standard for New Jersey," said Guy P. Evans, vice president of business development for NJHA. "We have an obligation to offer our members proven technology for regulatory compliance and we are pleased to continue to offer our members and partners such a highly reliable and secure email encryption solution. ZixCorp's ability to provide instant, secure communication with our partners, employees and association customers through ZixDirectory is what makes them our preferred choice for Email Encryption."

About New Jersey Hospital Association

Headquartered in Princeton, N.J., the New Jersey Hospital Association (http://www.njha.com) supports its 105 member hospitals through advocacy, education, data resources, and other services so they can continue their mission of providing affordable, accessible, and quality healthcare. Dedicated to quality improvements, NJHA has collaborated with federal and state governments, physician groups, consultants and others to address healthcare quality concerns. Additional efforts in the quality arena include continuing education, ongoing efforts in data collection, and benchmarking and the formation of a Quality Institute to continue developing member resources in quality improvement. For more information, please visit http://www.njha.com.

FINISAR CORPORATION. (NASD: FNSR)
Up 8.40% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=FNSR

Finisar Corporation (Nasdaq:FNSR) is a global technology leader for fiber optic components and subsystems and network performance test systems. These products enable high-speed data communications for networking and storage applications over Gigabit Ethernet Local Area Networks (LANs), Fibre Channel Storage Area Networks (SANs), and Metropolitan Area Networks (MANs) using Fibre Channel, IP, SAS, SATA and SONET/SDH protocols. The Company's headquarters is in Sunnyvale, CA, USA. Finisar has approximately 4,500 employees. For more information, visit http://www.Finisar.com.

Recent FNSR News:

July 1, 2008 - Finisar and Optium Announce Early Termination of Hart-Scott-Rodino Act Waiting Period for Proposed Merger

Finisar Corporation (Nasdaq:FNSR) and Optium Corporation (Nasdaq:OPTM) today announced that the U.S. Department of Justice and Federal Trade Commission have granted Finisar early termination of the Hart-Scott-Rodino (HSR) waiting period in conjunction with the proposed combination of the two companies. The merger remains subject to satisfaction of other conditions, including approval of the stockholders of both Finisar and Optium.

On May 16, 2008, Finisar and Optium jointly announced that they had entered into a definitive agreement under which the two companies will be combined through an all-stock merger, creating the world's largest supplier of optical components, modules and subsystems for the communications industry. The combined company will leverage Finisar's leadership position in the storage and data networking industries and Optium's leadership position in the telecommunications and CATV industries.

‘Before the Bell’ for Tuesday, July 1st, 2008

On the Radar: MYRL, GYGC, PRPL, DLKM, PPHM, ZHNE

This morning's top Micro Cap trading ideas include, Military Resale Group, Inc. (OTCPK: MYRL), Guyana Gold Corp. (OTCPK: GYGC), Park Place Energy Corp. (OTCBB: PRPL), Douglas Lake Minerals, Inc. (OTCBB: DLKM), Peregrine Pharmaceuticals, Inc. (NASD: PPHM), Zhone Technologies, Inc. (NASD: ZHNE).

MILITARY RESALE GROUP, INC. (OTCPK: MYRL)

Up 66.67% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=MYRL.PK

Military Resale Group, Inc. (MYRL) operated for over eight years as a specialist in military distribution. MYRL formed a new subsidiary company, Military & Specialty Distributors, Inc. ("MSDI"). MSDI will focus on the planned expansion as a national distributor to service commissaries and retail services throughout the DeCA system, and the 13.7 million patrons who purchase $5 billion in products each year. MSDI has identified numerous new products to market that will bring the company new revenues and better profit margins than in the past. The company has also begun to expand its retail operations which now mirror the expanded Military Resale Group wholesale operations. Military Resale Group historically sold a wide variety of grocery and household items.

Recent MYRL News:

June 30, 2008 - Military Resale Group, Inc. Announces Recent Progress and Updates

Military Resale Group, Inc. (PINKSHEETS: MYRL) announced today that the Company is in final negotiations to acquire two major food distribution contracts for the Northeast United States. These new product lines will initially be distributed by companies with existing relationships with MYRL and its subsidiaries. MYRL also announced that it is close to securing a significant credit facility which will enable the Company to further implement its growth plan.

Nick Kontonicolas, Chairman of MYRL, stated, "We have been working diligently to restructure the Company to be not only a distributor of food products to the U.S. Military commissary system but a significant distributor of specialty and ethnic foods and new products being introduced to the market." Mr. Kontonicolas added, "We will be happy to review and plan the distribution of any new and interesting food or beverage product that is presented to us. You can contact me personally at ctradeusa@juno.com with your offers."

GUYANA GOLD CORP. (OTCPK: GYGC)
Up 8.70% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=GYGC.PK

Guyana Gold Corp. is a junior mineral exploration company that specializes in identifying, acquiring and developing precious and base metal properties as well as assessing whether certain claims possess exploitable commercial and precious mineral reserves. The Company's objective is to develop a balanced global portfolio of early-to-advanced stage projects. Guyana is currently focused on gold projects in the Caribbean. In Guyana, the Company's key mineral project is located in the region of Port Kaituma.

Recent GYGC News:

June 30, 2008 - Guyana Gold Corp. to Cancel 114,250,000 of Its Common Shares of the Company Stock

Guyana Gold Corp. (OTC: GYGC-News) is pleased to announce that a decision has been made to cancel 114,250,000 common shares. This cancellation will reduce the company's outstanding shares from 165,038,947 to 50,788,947, which represents approximately 70% of the issued and outstanding shares.

Eduard Aronov, President of Guyana Gold Corp., commented that, "This action to reduce the company's issued and outstanding shares shows the great commitment level management has for its shareholders and to the future growth of the company." Additionally he noted, "I am confident that our future revenue stream will continue to produce results that our shareholders have come to expect. These things, combined with other exciting events we see in the very near future, should make the next couple of years very exciting for Guyana Gold Corp."

PARK PLACE ENERGY CORP, INC. (OTCBB: PRPL)
Up 40.94% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=PRPL.OB

Park Place Energy Corp. is a North American oil and gas company that is participating in high impact opportunities. The Company currently has gas production in North-East British Columbia and is committed to developing the asset as well as acquiring additional blue-sky gas opportunities in the area, with a focus on shale gas. Park Place's management is focused on optimizing profitability and enhancing shareholder value.

Recent PRPL News:

June 30, 2008 - Park Place Energy Corp. Revenues Surpass Expectations with Significant Cash Flow

Park Place Energy Corp. ("Park Place" or "the Company") is pleased to announce that revenues from production for the month of May have surpassed $260,000 CDN. Additionally, the company is waiting for confirmation with respect to the liquids of approximately 19 barrels per million cubic feet. Production is coming from the Company's core property, Eight Mile, in North East British Columbia where the Company and its partners have tied in the 7 of 8 Well.

With natural gas prices strengthening well over $13 MMBTU this summer and crude oil running well over $140 per barrel, market conditions appear promising for the development of Canada's immense petroleum resources. Park Place has positioned itself in North East British Columbia and has created a core area around its Eight Mile gas property and has a highly experienced operating partner in Terra Energy (TSX.V:TTR).

With the Company now generating significant cash flow for the first time in its history as a public company, Park Place and its partners will review the recently acquired 3D seismic data on the Eight Mile Property over the upcoming weeks and decisions will be made as to where to drill additional earning and step out wells. Park Place is also aggressively seeking to acquire a shale gas property with blue sky potential with a focus on the Horn River Basin and area near its producing Eight Mile property.

Park Place Energy President and CEO David Johnson said, "This is a very exciting time for Park Place with significant cash flow and we have graduated from being a junior explorer to a substantial producer in our core area, North Eastern British Columbia"

DOUGLAS LAKE MINERALS, INC. (OTCBB: DLKM)
Up 35.35% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=DLKM.OB

DLKM is an emerging mineral exploration company focused on exploring and developing gold, copper, nickel, uranium and diamond mining opportunities in Tanzania. DLKM has a portfolio of 51 prospecting concessions.

Recent DLKM News:      

June 30, 2008 - Douglas Lake Minerals Successfully Closes Acquisition of Mbwemkuru Project

Harp Sangha, CEO and President of Douglas Lake Minerals Inc. (DLKM-OTCBB) announced today that the company has closed the acquisition of the Mbwemkuru Alluvial Gold Project Licences in the Lindi region in Southeastern Tanzania.

The Prospecting Licences are situated in the SE margin of the Karoo Basin and cover an area of 430 square kilometers. The property is currently in small scale production by the owner. One of the most significant prospects is an eight by two kilometer block, with high gold concentrations within 1.0 and 1.5 meter zones between the gravel and bedrock. Results of initial systematic sampling of alluvium as reported by Echo Tech Laboratories showed an average grade of 9.48 g/t gold.

The vendor of the property will receive $1,000,000.00 USD, a 3% Net Smelter Return (NSR), and a five year employment contract, totaling $540,000.00 USD. The necessary funding was provided by the Tianjin Institute of Geology and Mineral Resources (TIGMR).

"We are extremely pleased with this new acquisition and we are looking forward to announcing further assay results in the near future," stated Harp Sangha.

PEREGRINE PHARMACEUTICALS, INC. (NASD: PPHM)                                    Up 13.54% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=PPHM

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Recent PPHM News:

June 30, 2008 - Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC). The primary objective of the study is to assess the overall response rate to the combination of bavituximab with a standard regimen of carboplatin and paclitaxel in NSCLC patients. The multi-center clinical trial is being conducted in India.

"The initiation of patient enrollment and dosing in our trial of bavituximab in combination with chemotherapy in lung cancer patients marks an important milestone in our Phase II bavituximab clinical program," said Steven W. King, president and CEO of Peregrine. "We are eager to test the combination of bavituximab with carboplatin and paclitaxel in these patients, since 50% of advanced cancer patients treated with this combination in our Phase Ib trial achieved an objective tumor response. We look forward to learning more about bavituximab's potential in NSCLC, an important new indication that is a leading cause of cancer deaths for both men and women."

In the trial's two-stage design, up to 21 patients with NSCLC will be enrolled initially. The study will then be expanded up to a total of 49 patients if promising results are observed in the initial cohort. Secondary objectives of the study include time to tumor progression, duration of response, overall patient survival and safety parameters. Tumor response in the study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. Patients may continue to receive bavituximab as long as the cancer does not progress and side effects are acceptable.

The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

Lung cancer is a major cause of cancer deaths worldwide. According to the American Cancer Society, in the U.S. lung cancer is the second most commonly diagnosed cancer in men and women and is the leading cause of cancer deaths. It estimates that in the U.S. in 2008, there will be approximately 215,400 new cases of lung cancer and an estimated 161,800 lung cancer deaths. Non-small cell lung cancer, or NSCLC, is the most common type of lung cancer, accounting for approximately 85-90% of lung cancer cases.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in Phase II combination therapy trials for the treatment of advanced breast cancer and non-small cell lung cancer and a second Phase II trial in breast cancer is expected to begin soon. In a Phase Ib trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A Phase I bavituximab monotherapy trial in advanced solid cancers is continuing.

ZHONE TECHNOLOGIES, INC. (NASD: ZHNE)
Up 11.43% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=ZHNE

Zhone Technologies, Inc. (NASDAQ:ZHNE) is a global leader in multi-service access network solutions, serving more than 700 of the world's most innovative network operators. The company offers the industry's broadest fully-integrated portfolio of MSAP, FTTx, EFM and Wi-Fi access technologies, enabling a full suite of services, including residential and business broadband, VoIP, and High-Definition IPTV. Zhone's converged multi-service access platform helps operators rapidly deploy premium services using copper, fiber, and wireless while improving network agility and reducing costs. www.zhone.com

Recent ZHNE News:

June 30, 2008 - Zhone MDU Solutions Gain Traction With Aggressive Growth CLEC Maskatel in Quebec

Zhone Technologies, Inc. (NASDAQ:ZHNE), a global leader in multi-service access solutions, today announced that leading Quebec CLEC Maskatel has selected Zhone's next-generation MALC(TM) 1U POTS/DSL platform to provide high-speed services to Multi-Dwelling Units (MDUs). Zhone's 1 Rack Unit (RU), 48 port configuration of voice and ADSL2+ ports with Ethernet uplinks is uniquely suited to the MDU play. Maskatel cited Zhone's robust platform, superior interoperability and plug and play configuration as deciding factors against competing platforms.

Zhone's 1U MALC design provides the field-proven performance of Zhone's multi-service access platform with the latest in processor speeds and chipset evolution for both voice and data services. The product is fully triple-play compatible and comes with Zhone's new easy to use embedded web browser, making the system simple to configure and activate.

"Our business is evolving rapidly in a very competitive market space," said Donald Dupuis, president of Maskatel. "We needed a vendor with cutting edge abilities, based on a mature and stable platform that was price competitive and ready to go. We found Zhone to be the triple winner. The platform fits all of our needs right out of the box."

"Maskatel is an ideal customer for our 1U MALC product design," said Steven Glapa, VP of product management and marketing for Zhone. "We did a lot of active listening before we delivered on the product and it's paying off in real interest based on ease of install, value and feature set. CLECs and IOCs alike are impressed with what we've crafted and the price point. It's not just a game of speeds and feeds, but of making the overall business fit."

About Maskatel, Telephone Drummond, and Telephone Guevremont

On the Radar: LLSR, PSPM, SOLM, GLOB, VLNC, HYGS

This morning's top Micro Cap trading ideas include, Lantis Laser, Inc. (OTCPK: LLSR), Purespectrum, Inc. (OTCPK: PSPM), Solomon Technologies, Inc. (OTCBB: SOLM), Global, Med Technologies, Inc. (OTCBB: GLOB), Valence Technology, Inc. (NASD: VLNC), Hydrogenics Corp. (NASD: HYGS).

Featured Pick

LANTIS LASER, INC. (OTCPK: LLSR)

Up 0.00% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=LLSR.PK

Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 and Phase 3 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System(tm) in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser (Pink Sheets:LLSR), visit www.lantislaser.com

Recent LLSR News:

June 26, 2008 - Lantis Laser's Dental Diagnostic Imaging System Can Address ADA's Recommendations for Placement of Sealants

Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com), wishes to draw attention to new, recently introduced, clinical recommendations from the American Dental Association Council on Scientific Affairs to assist clinicians in their decision-making process, for the use of composite plastic sealants over very early decay on the occlusal biting surface of teeth in children, adolescents and young adults to stop the disease from progressing.

"Placing sealants on the biting surfaces can stop early decay that is still in the enamel from progressing," pointed out Dr. Craig Gimbel, Executive Vice President of Clinical Affairs for Lantis Laser. "This article mentions that the clinician may be uncomfortable to make the decision to place a sealant because of unavailable adequate diagnostic tools for diagnosis and monitoring to ascertain if the sealant will be placed on top of existing decay in the enamel."

Dr. Gimbel went on to emphasize that, "Presently, the only accepted way to ascertain if decay is present is by recognition of tooth surface color changes, which can be misinterpreted as stains or defects instead of decay or possibly decay when it didn't exist at all." It is well documented that x-rays do not generally have the ability to image very early decay, which is important for the success of this procedure.

It is important to note that the ADA states that clinicians should not obtain radiographs for the sole purpose of placing sealants and should consult the ADA/U.S. Food and Drug Administration guidelines regarding selection criteria for dental radiographs which places limitations due to risk of radiation.

Lantis' OCT (Optical Coherence Tomography) Diagnostic Imaging System(tm) will assist the clinician in making an evidence-based decision to place the sealant because of its ability to image early decay and subsurface enamel changes which is indicative of the demineralization, the first stage in the process of decay.

In addition, it will enable the dentist to monitor the sealed tooth surface area in order to determine that this non surgical method of arresting the decay has been effective. Clinical studies have shown that Lantis' OCT Diagnostic Imaging System(tm) is the only dedicated dental imaging system that can provide evidence for early decay demineralization and then follow the process of remineralizing as the bacteria die under the placed sealant, all without the risk of radiation. The placement of sealants will enable patients to possibly avoid invasive dental procedures, such as fillings, that are associated with later stage decay.

Lantis' OCT Dental Imaging System(tm) is based on novel light-based, bio-medical imaging technology, Optical Coherence Tomography, that enables the dentist to do diagnostic imaging, chairside and in real-time. As the power source is light-based, unlike x-ray there is no harmful radiation. Images can be captured at a resolution of up to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects.

PURESPECTRUM, INC. (OTCPK: PSPM)
Up 22.73% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=PSPM.PK

PureSpectrum (PINKSHEETS: PSPM) is a publicly traded technology company founded and headquartered in Savannah, Ga. The company's values are grounded in an awareness of the increasing urgency to identify more efficient energy solutions. PureSpectrum currently holds the rights to multiple patents and patent applications related to an electronic ballast design which would produce a soft switching environment during power conversion for artificial lighting. PureSpectrum will continue its commitment to researching, developing and refining ideas that will provide the most energy efficient, cost effective methods for powering artificial light. For more information on PureSpectrum, please call (912) 961-4980 or visit www.purespectrumlighting.com.

Recent PSPM News:

June 26, 2008 - PureSpectrum, Inc. Issued New Patent for High Frequency Electronic Ballast

PureSpectrum, Inc. (PINKSHEETS: PSPM) was recently awarded a full patent for a high frequency, high efficiency electronic ballast with a sine wave oscillator that further strengthens the company's patent portfolio.

The issuance of the patent is the latest demonstration of PureSpectrum's ongoing effort to reinforce corporate organization and infrastructure as the company prepares for expanded operations. PureSpectrum owns the rights to a family of patents and patent applications related to electronic ballast technology engineered to address both manufacturability and functionality. During the first two quarters of 2008 the company has been engaged in licensing discussions with multiple major lighting manufacturers regarding proprietary dimmable ballast circuitry for Compact Fluorescent Light (CFL) bulbs, linear fluorescent lamps as well as a proprietary design for a dimming device.

Patent 7,388,334 is one of multiple circuitry technologies identified by PureSpectrum which provide a diverse range of performance benefits for fluorescent lighting. The patent describes a high efficiency electronic ballast that is addressable to all gas discharge lighting applications.

As the company focuses on marketing the most recent iterations of its technology, PureSpectrum president and CEO Lee Vanatta said it is critical for the company to continue diligently protecting the base science which was the foundation for the company's technology breakthroughs. The issuance of patents also further strengthens PureSpectrum's position in ongoing licensing discussions with lighting manufacturers.

"We are firmly committed to protecting all aspects of PureSpectrum's intellectual property to ensure the most possible avenues for revenue generation and guarantee our shareholders that this company is thoroughly prepared for rapid growth," Vanatta said. "This patent represents our advance technology team's initial discoveries in properly controlling wave forms within the ballast to reduce the heat and energy losses in order to direct more power to the generation of light."

Go to www.purespectrumlighting.com or www.pinksheets.com for more information about PureSpectrum or to view PureSpectrum's full financial documentation through December 31, 2007. Call (912) 961-2980 with inquiries regarding PureSpectrum or PureSpectrum Technology.

SOLOMON TECHNOLOGIES, INC. (OTCBB: SOLM)
Up 37.50% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=SOLM.OB

Solomon Technologies, Inc., through its Motive Power and Power Electronics divisions, develops, licenses, manufactures and sells precision electric power drive systems, including those utilizing its patented Electric Wheel(R) Electric Transaxle(TM) and hybrid and regenerative technologies as well as direct current power supplies and power supply systems requiring high levels of reliability and ruggedness for defense, aerospace, marine, commercial, automotive, hybrid electric and all electric vehicle applications.

Recent SOLM News:

June 26, 2008 - Solomon Systems Commissioned in Singapore

Solomon Technologies, Inc. (OTC Bulletin Board: SOLM) today announced that the first eight water taxis using Solomon's ST-74 marine propulsion systems have been commissioned for operations in the rivers and harbor areas of Singapore. Solomon worked with the marine constructor in Singapore to provide a powerful, environmentally friendly system, using its proprietary propulsion technology.

Peter W. DeVecchis, President of Solomon commented, "We are pleased that the installation and operation of these systems went so smoothly. We designed them for simplicity of installation in remote environments without the need for factory assistance on-site. Our customer required very little guidance in installing and making the systems operational in record time." He continued, "We intentionally designed these products with the goal of having them operate almost universally, within certain power requirements, in various hull configurations, similar to the 'Plug & Play' concept in the electronics industry. We believe our product performance will lead to additional orders to complete the project."

GLOBAL MED TECHNOLOGIES, INC. (OTCBB: GLOB)
Up 18.10% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=GLOB.OB

Global Med Technologies(R), Inc. is an international e-Health medical information technology company providing information management software products and services to the healthcare industry. Its Wyndgate Technologies(R) division is a leading supplier of information management systems to U.S. and international blood centers and hospital transfusion centers. Each year, Wyndgate's products and services manage more than eight million blood components, representing over 27% of the U.S. blood supply. Wyndgate's products are also being used in Canada, Africa, and the Caribbean. Wyndgate's software provides Vein-to-Vein(R) tracking from donor collection to patient transfusion through its Donor Doc(TM) interactive donor health history questionnaire, ElDorado Donor(TM) and SafeTrace(R) donor management systems, to its SafeTrace Tx(R) advanced transfusion management system. Global Med's PeopleMed(R), Inc. subsidiary provides custom software validation, consulting and compliance solutions to hospitals and blood centers. PeopleMed's in-depth knowledge of Wyndgate's products and the blood banking industry results in cost-effective validation services, which leads to more efficient software implementations and upgrades for our customers.

Recent GLOB News:      

June 26, 2008 - Global Med Technologies(R), Inc. Completes Acquisition of Inlog, SA, a Leading European Medical Software Firm

Global Med Technologies(R), Inc. ("Global Med" or the "Company") (OTC Bulletin Board: GLOB), an international e-Health, medical information technology company, today announced the completed acquisition of Inlog, SA, and its German and related subsidiary ("Inlog"), a private European medical software firm, for a maximum of $11.5 million in a combination of cash, stock and earnout. The structure of this transaction is expected to be accretive, exclusive of financing costs, in the first full year of operations. Inlog's management is planning to stay with the Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO)

Inlog, based in Lyon, France, with additional operations in Grenoble, France, and Munich and Alzey, Germany, is a leading European provider of donor center and transfusion information management systems as well as laboratory information systems and other ancillary medical software systems. Inlog currently maintains 700 sites in 15 countries.

Inlog's shareholders must use $500,000 of the cash proceeds to purchase Global Med common stock in the open market within three months of the closing. Inlog's unaudited revenues for their fiscal year ended June 30, 2007 were approximately euro 7.0 million* or about $12.4 million at current exchange rates, with EBITDA of approximately euro 940,000* or approximately $1.45 million. Inlog's unaudited revenues for the nine months ended March 31, 2008 were approximately euro 6.6 million or about $10.2 million at current exchange rates, with EBITDA of approximately euro 780,000 or approximately $1.2 million. Global Med will utilize a combination of existing cash and debt to pay for the transaction.

Chairman and CEO of Global Med Technologies, Inc., Michael I. Ruxin, M.D., stated, "The acquisition of Inlog by Global Med is a transforming event in the history of our Company. As a leading provider of blood and laboratory software applications in 20 countries (in the U.S., Canada, Caribbean, European Union, Africa, French Polynesia, and New Caledonia) we are now poised to grow our Company in the global marketplace and react quickly to a rapidly changing international market." Dr. Ruxin continued, "The accretive nature of the transaction will also further strengthen Global Med's financial position and propel the Company to develop more next-generation medical software solutions." Dr. Ruxin further stated, "With the combination of Global Med and Inlog, we know of no other company, domestic or international, that brings the breadth and depth of blood-related software applications to the world market. Our new international suite of software products contains eleven applications that will permit us to grow our global presence."

Interest has been generated on both sides of the Atlantic for products from Inlog and Global Med's U.S.-based division, Wyndgate Technologies. Particular notice has been shown by U.S. institutions for Inlog's EdgeCell software, a Cellular Therapy application for tissue banks, stem cell centers and cord blood centers. EdgeCell has received the European designation, NF/ISO 25051/12119 certification, assuring the highest level of quality regarding the design, the testing and validation of the software, the documentation quality and the quality of support and maintenance.

Inlog's product line also includes EdgeBlood** (also known as CTS Serveur, for the donor center marketplace), EdgeTrack** (for the hospital transfusion marketplace), EdgeLab (Laboratory Information System "LIS"), and SAPA (supports regulatory compliance and document management). Inlog is ISO 9001:2000 certified and these products have also received the NF/ISO 25051/12119 certification.

Inlog has a substantial blood center and transfusion market share in France, Germany, Austria, Belgium and Switzerland and installations in Greece and Monaco. In Africa, Inlog supplies its blood center and transfusion systems to the National Blood Services of Gabon, Burkina Faso and Senegal, as well as having installations in Algeria, the Ivory Coast and Rwanda. Inlog's EdgeLab, with 130 laboratory sites in France, is gaining market share in Germany, Spain, Belgium, the Middle East and Asia. There are no current plans to bring EdgeLab into the U.S.

Thomas F. Marcinek, the Company's President and COO, stated, "We are excited to have Inlog join the Global Med group of companies. As Inlog has significantly grown their market share, this acquisition doubles our customer base. Inlog's experience in handling international implementations and their cutting edge software solutions complement our current offerings and expand Global Med's market presence. Furthermore, EdgeCell, Inlog's successful cellular therapy software, will fulfill an immediate need for our customers in the U.S. market." Mr. Marcinek added, "We have respect and admiration for the Inlog management and staff and their attention to customer service. The synergistic value of bringing two strong organizations together will result in innovative solutions and continued dynamic growth."

Renaud Blanc-Bernard of Inlog commented, "On behalf of Inlog, we are all very pleased to join forces with Global Med. Becoming an international group of almost 200 people, present in 20 countries and maintaining 1,400 transfusion centers, blood banks and laboratories, we're developing our human, commercial and technical strengths while providing the capacity to handle large national implementations anywhere in the world." Mr. Blanc-Bernard further stated, "With the synergies between our two companies, we have now more than doubled the development capabilities of Global Med and are already seeing increased interest in our collective systems in the international marketplace. Our inaugural joint marketing efforts at the ISBT international conference in Macao, China were well received. We were also quite pleased at the interest shown in our products during a recent conference in the United States and we recognize the strategic advantages in providing an enhanced product line to customers."

VALENCE TECHNOLOGIES, INC. (NASD: VLNC)                                                Up 19.44% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=VLNC

Valence developed and markets the industry's first commercially available, safe, large-format family of lithium phosphate rechargeable batteries. Valence holds an extensive, worldwide portfolio of issued and pending patents relating to its lithium phosphate rechargeable batteries. The company has facilities in Austin, Texas; Las Vegas, Nevada; Mallusk, Northern Ireland and Suzhou, China. Valence is traded on the NASDAQ Capital Market under the ticker symbol VLNC and can be found on the internet at www.valence.com.

Recent VLNC News:

June 26, 2008 - Valence Technology Receives Qualified Opinion from Its Auditors

Valence Technology, Inc. (NASDAQ:VLNC) today reported that, with respect to the financial statements included in the company's Annual Report on Form 10-K for the fiscal year ended March 31, 2008, the audit opinion of PMB Helin Donovan, LLP, the company's independent registered public accounting firm, contained a "going concern" qualification. The company also received a "going concern" qualification for the fiscal year ended March 31, 2007.

NASDAQ Marketplace Rule 4350(b)(1)(B) requires NASDAQ-listed companies to publicly announce through the news media the receipt of an audit opinion containing a "going concern" qualification. This announcement does not represent any change or amendment to the company's fiscal year 2008 financial statements, the Annual Report on Form 10-K, or to any statements made during the company's June 5, 2008 conference call to discuss its fiscal 2008 and fourth quarter financial results.

The Company's Annual Report on Form 10-K is available from the SEC's website at www.sec.gov.

HYDROGENICS CORP. (NASD: HYGS)
Up 10.34% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=HYGS

Hydrogenics Corporation (www.hydrogenics.com) is a globally recognized developer and provider of hydrogen generation and fuel cell products and services, serving the growing industrial and clean energy markets of today and tomorrow. Based in Mississauga, Ontario, Canada, Hydrogenics has operations in North America, Europe and Asia.

Recent HYGS News:

June 26, 2008 - Hydrogenics Provides Clean Energy Hydrogen Generation System to Shell-Hydrogen for California Hydrogen Highway

Hydrogenics Corporation (TSX: HYG) (NASDAQ: HYGS), a leading designer and manufacturer of hydrogen electrolyzers and fuel cell systems, today announced that it has provided an integrated hydrogen generation system to Shell Hydrogen LLC. The fueling station, which opened today in Los Angeles as part of California's Hydrogen Highway initiative, will generate hydrogen on site to service the increasing demands of hydrogen-powered consumer vehicles.

Hydrogenics provided an integrated hydrogen fueling station, based on its highly modular standard product line, including electrolyzer, compressor, storage, and dispensing systems. In order to meet the demanding space requirements of the fueling station, Hydrogenics implemented a canopy system where all the components are mounted on the roof of the station canopy, minimizing the footprint of the hydrogen station. In addition, Hydrogenics' electrolyzers produce hydrogen from water, providing the most environmentally friendly approach to hydrogen generation.

California is the most developed state in the U.S.A. in terms of Hydrogen energy, reflected by Governor Swartzeneger's promise of 200 Hydrogen refueling stations in California before he retires. "The experience gained in our 50-year history positions Hydrogenics to meet the rapid growth of the Hydrogen highway," said Daryl Wilson, President and CEO of Hydrogenics. "Our modular product offering is highly scaleable and configurable to meet widely varying requirements," added Wilson. Hydrogenics has installed over 30 fueling stations deriving hydrogen through electrolysis, which is the most environmentally friendly approach to hydrogen generation.

Lantis Laser's Dental Diagnostic Imaging System Can Address ADA's Recommendations for Placement of Sealants

OCT Can Provide Diagnostic Imaging Information Needed for Dentist's Confidence in Placing Sealants

June 26, 2008 9:00:00 AM

DENVILLE, N.J., June 26, 2008 (PRIME NEWSWIRE) -- Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com), wishes to draw attention to new, recently introduced, clinical recommendations from the American Dental Association Council on Scientific Affairs to assist clinicians in their decision-making process, for the use of composite plastic sealants over very early decay on the occlusal biting surface of teeth in children, adolescents and young adults to stop the disease from progressing.

"Placing sealants on the biting surfaces can stop early decay that is still in the enamel from progressing," pointed out Dr. Craig Gimbel, Executive Vice President of Clinical Affairs for Lantis Laser. "This article mentions that the clinician may be uncomfortable to make the decision to place a sealant because of unavailable adequate diagnostic tools for diagnosis and monitoring to ascertain if the sealant will be placed on top of existing decay in the enamel."

Dr. Gimbel went on to emphasize that, "Presently, the only accepted way to ascertain if decay is present is by recognition of tooth surface color changes, which can be misinterpreted as stains or defects instead of decay or possibly decay when it didn't exist at all." It is well documented that x-rays do not generally have the ability to image very early decay, which is important for the success of this procedure.

It is important to note that the ADA states that clinicians should not obtain radiographs for the sole purpose of placing sealants and should consult the ADA/U.S. Food and Drug Administration guidelines regarding selection criteria for dental radiographs which places limitations due to risk of radiation.

Lantis' OCT (Optical Coherence Tomography) Diagnostic Imaging System(tm) will assist the clinician in making an evidence-based decision to place the sealant because of its ability to image early decay and subsurface enamel changes which is indicative of the demineralization, the first stage in the process of decay.

In addition, it will enable the dentist to monitor the sealed tooth surface area in order to determine that this non surgical method of arresting the decay has been effective. Clinical studies have shown that Lantis' OCT Diagnostic Imaging System(tm) is the only dedicated dental imaging system that can provide evidence for early decay demineralization and then follow the process of remineralizing as the bacteria die under the placed sealant, all without the risk of radiation. The placement of sealants will enable patients to possibly avoid invasive dental procedures, such as fillings, that are associated with later stage decay.

Lantis' OCT Dental Imaging System(tm) is based on novel light-based, bio-medical imaging technology, Optical Coherence Tomography, that enables the dentist to do diagnostic imaging, chairside and in real-time. As the power source is light-based, unlike x-ray there is no harmful radiation. Images can be captured at a resolution of up to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects.

About Lantis Laser

Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently entering Phase 3 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System(tm) in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser (Pink Sheets:LLSR), visit www.lantislaser.com

About Eclipse Product Development

Eclipse, located in Amesbury, MA has over 13 years of experience helping clients commercialize medical, laboratory and dental category technologies. The company is medically oriented and has designed numerous products including complex diagnostic and therapeutic medical and dental equipment and devices. Their development process meets FDA and ISO requirements for design control documentation and verification. Eclipse has developed a strategic business model to include several experienced molding and manufacturing vendor relationships.

Safe Harbor: Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the safe harbors created thereby. The Company is a development stage company who continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.

CONTACT:  Lantis Laser Inc.           Stan Baron, President & CEO           (203) 300-7622           sbaron@lantislaser.com            AGORACOM Investor Relations           http://www.agoracom.com/ir/lantislaser           llsr@agoracom.com            For OCT Updates           http://www.octnews.hivefire.com 

On the Radar: PLFM, AMHI, GNTA, SIBM, DCTH, TSYS

This morning's top Micro Cap trading ideas include, Platforms Wireless Intl. Corp. (OTCPK: PLFM), American Healthchoice, Inc. (OTCPK: AMHI), Genta, Inc. (OTCBB: GNTA), Silver Butte Mining Co.. (OTCBB: SIBM), Delcath Systems, Inc. (NASD: DCTH), TeleCommunication Systems, Inc. (NASD: TSYS).

PLATFORMS WIRELESS INTL. CORP. (OTCPK: PLFM)

Up 62.50% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=PLFM.PK

Platforms Wireless International Corporation, headquartered in Westlake Village, California, is the developer of the innovative airborne wireless communications core technology known as the Airborne Relay Communications "ARC" System Core Technology(TM). The ARC System Core Technology(TM) can provide wide area wireless telecommunications services from a High Altitude Wireless Communications System ("HAWCS(TM)") platform, using Transportable, Mobile Tall Towers and/or Transportable, Mobile Aerostats as the System delivery vehicles.

RECOM-911(TM) -- the "Rapid Response Emergency Communications System(TM)," is the Company's principal system product: a high altitude, rapid response emergency communications system that can be readily deployed to critical emergencies and natural or man-made disasters where the communications infrastructure has been compromised or completely destroyed. The System is designed to provide a transportable cellular voice, data, video and sensor communications network designed to provide cellular and interoperable radio communications facilities for emergency first responders. RECOM-911(TM) can automatically create a private, autonomous, voice, data, video, and sensor communications network by linking up to ten system units positioned up to 20 miles apart from each other. The Transportable Tower System provides up to a 15-mile radius geographical coverage (depending on terrain and line-of-sight), with a service capacity of up to 50,000 users, and it can interconnect with the PSTN via cable, fiber, and microwave or satellite link, as required.

ROSETTA-911(TM), the "Radio Open System Electronic Translation and Transmission Architecture" system, provides advanced radio communications interoperability between VHF, UHF, 800 MHz radios, including cellular and land line telephones, as well as Internet/VOIP communications connectivity. The ROSETTA-911(TM) System can operate as a portable, autonomous interoperable radio communications field station, or it can be deployed aboard a Transportable Aerostat or Tall Tower, to operate in conjunction with the RECOM-911(TM) Cellular Communications System.

Platforms Wireless believes its rapid-response High Altitude Wireless Communications Systems(TM) ("HAWCS(TM)") can provide advanced, cost-effective, voice, data, video, and sensor communications solutions for military, commercial, and critical emergency applications, particularly for natural or man-made disasters, where communications infrastructures have been compromised or completely destroyed. RECOM-911(TM) can also be used as a cost-effective commercial telecommunications solution to strategically augment and/or supplement terrestrial land-line and wireless telecommunications infrastructures, and to rapidly and profitably penetrate new market areas.

Recent PLFM News:

June 24, 2008 - Platforms Wireless Completes 6-Year Independent Audit for Issuance of Certified Financial Statements and Filing of S-1 Registration Statement

Platforms Wireless International Corporation (Pink Sheets:PLFM) (www.plfm.net) announced today that its independent auditors have completed their field work on a six-year, comprehensive audit of the company's financial statements. The independent audit required more than two years to complete, and it covers the fiscal years ended June 30, 2002 through June 30, 2007. The audit was conducted by Farber Hass Hurley LLP, a PCAOB registered accounting firm headquartered in Camarillo, California.

President Charles B. Nelson commented: "I would like to thank our auditors and everyone involved in this long and challenging process for their hard work and dedication to see this critical task completed. We expect to publish the Company's audited financial statements for the fiscal years ended June 30, 2002 through June 30, 2007 in July.

"The further independent audit of the Company's records for the current fiscal year ending June 30, 2008, as well as the publication of corresponding financial statements, should be completed by September 30, 2008."

With the completion of the Company's independent audit, management intends to file its S-1 Registration Statement and apply for listing on the OTC Bulletin Board. Management expects to file the Company's S-1 Registration Statement in the third quarter of 2008.

President Charles B. Nelson pointed out: "It is important for our shareholders to note that the Company's research and development efforts, since the Company's inception in 1992 through June 30, 2007, were costly to the bottom line, but they have produced advanced high-altitude wireless communications core technology and derivative wireless communications products for military, commercial, and emergency communications applications.

"In addition," President Charles B. Nelson concluded, "once the Company completes and files its income tax returns to reflect the audited results for these periods, we expect to have a substantial Net Operating Loss ('NOL') carry-forward benefit available to offset future income taxes on our operations."

AMERICAN HEALTHCHOICE, INC. (OTCPK: AMHI)
Up 100.00% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=AMHI.PK

The Company began operations in 1994 and has since grown substantially, paying off debt, increasing revenues and constantly searching for new medical-based solutions. American HealthChoice operates as both AHC Medical and RehabCo.

The medical clinics are located throughout the Southeast USA. We presently own and operate 8 company-owned clinics and have another 35 clinics in our Affiliated Clinic Program. We recently sold a number of clinics in order to pay off debt and bolster our ability to build new revenue producing business entities. TelmedCo provides second opinions to company-owned and affiliated clinics as well as four clinics outside the Division's network.

RehabCo recently reorganized from providing spinal decompression technology to becoming a world class provider of state-of-the-art medical equipment. RehabCo's mandate and challenge is to distribute and/or manufacture "revolutionary" new medical products at a cost substantially below other similar or competing products. To that end, we are constantly searching for those medical solutions that are years ahead of the competition.

The first medical equipment product that will be brought to the market through RehabCo is The OmniBody Scan, an absolutely revolutionary and unmatched infrared imaging solution. The OmniBody Scan is a product that highlights areas of abnormality within the body and directs both the clinician and patient to those areas for further diagnosis. The infrared image is non-invasive and has no harmful side effects. An X-ray, on the other hand, has potentially very harmful side effects from radiation. One of the major health problems that the OmniBody Scan will target is breast cancer. The sensitivity of the lens allows for a body scan image and detail not yet seen in a medical infrared imaging product. RehabCo also offers "image reading" services to both the patient and clinician through licensed thermographers. For more information, please go to RehabCo website.

Recent AMHI News:

June 24, 2008 - American HealthChoice CEO Dr. J.W. Stucki Provides Company Update

American HealthChoice, Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com, a medical services company with medical clinics in Texas and Tennessee, today, in an update for Company shareholders, said its net income for the six months ended March 31, 2008, totaled $32,300.

Net income for the second quarter ended March 31, 2008 totaled $47,300. The Company announced that patient billings from its four company-owned clinics and affiliated clinics totaled $2.5 million for the first six months of the current fiscal year.

Finally, the Company announced that it has reached agreement with its lender and debenture holders on a restructuring that will limit stock dilution. "With this restructuring, AMHI is positioned for future growth," said Dr. J.W. Stucki, Chairman and CEO. The Company said it will make cash payment of $7500 a month for the next 26 months as part of the restructuring.

Dr. Stucki said the Company will update shareholders on its telemedicine systems and its OmniBody scan in a news release soon.

                         American HealthChoice, Inc.

               Condensed Consolidated Statements of Operations

                                 (Unaudited)

                               Six months ended

                                         December      March        March

                                          2007 Q      2008 Q        2008

    Patient billings-Company-owned     $1,241,400   $1,215,500    $2,456,900

    Provision for discount on billings    696,600      675,900     1,372,500

    Net patient billings-Company-owned    544,800      539,600     1,084,400

    Net retained affiliated                71,000       71,000       142,000

    Net clinic billings                   615,800      610,600     1,226,400

    Clinic expenses                       450,700      405,900       856,600

    Corporate expenses                    159,100      136,400       295,500

    Total operating expenses              609,800      542,300     1,152,100

    Operating income                        6,000       68,300        74,300

    Other expenses                         21,000       21,000        42,000

    Net income (loss)                    $(15,000)     $47,300       $32,300

    Average common shares outstanding 153,000,000  160,000,000   157,000,000

GENTA, INC. (OTCBB: GNTA)
Up 31.76% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=GNTA.OB

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

Recent GNTA News:

June 24, 2008 - Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma

Genta Incorporated (OTC Bulletin Board: GNTA) announced the presentation of a progress update from an ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, the Company's lead oncology product, in patients with advanced melanoma. The data were presented at a satellite investigator's meeting held in conjunction with the Adjuvant Melanoma Congress sponsored by the European Association of Dermato-Oncology (EADO) in Marseille, France on June 21, 2008.

AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival. The trial is being led by the EADO in Europe and by the M.D. Anderson Cancer Center, Houston, TX in the U.S.

To date, more than one-third of the expected total number of patients have now been randomized onto the AGENDA trial. A total of 83 sites in 12 countries have been opened in Europe, the U.S., Canada, and Australia. Clinical characteristics of the first 70 patients accrued to AGENDA (not identified by treatment group) were shown to be similar to the biomarker-defined population accrued in the previous Phase 3 trial of Genasense, known as GM301. The incidence of serious adverse events in AGENDA has been somewhat lower, which probably reflects the routine use of prescribed supportive care for all patients, as well as the double-blind design of AGENDA compared with the open-label design of GM301. Target accrual of 300 patients is expected to complete in the fourth quarter of 2008, with initial data expected shortly thereafter.

About AGENDA

AGENDA is a global Phase 3, randomized, double-blind trial in patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from an antecedent randomized trial of Genasense combined with dacarbazine (DTIC) in patients who have not previously received chemotherapy (GM301). AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood. Analysis of those efficacy outcomes in GM301, which were observed in 274 patients, showed the following results:

                                                        Hazard

    Endpoint           Genasense/DTIC       DTIC         Ratio          P

    Overall response       20.8%            7.2%                      0.002

    Durable response       10.7%            2.4%                      0.007

    Progression-free      3.6 mos.        1.6 mos.        0.58      < 0.0001

     survival, median

    Overall survival,    12.3 mos.        9.9 mos.        0.64        0.0009

     median

A scientific article that describes efficacy and safety results from GM301 can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1

About the EADO

The EADO is an independent non-profit organization dedicated to the promotion, coordination, and improvement of clinical and laboratory research activities in the field of skin cancer. The organization has an European and international membership of dermatologists, oncologists and clinical as well as basic research scientists interested in the field of dermato-oncology. EADO provides leadership by formulating and disseminating quality standards and guide-lines for diagnosis and treatment of skin cancer, and it provides direction, coordination and organizations of clinical, therapeutic, and experimental trials.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

SILVER BUTTE MINING CO. (OTCBB: SIBM)
Up 25.00% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=SIBM.OB

Recent SIBM News:

June 24, 2008 - Silver Butte to Enter Coal Industry

On June 23, 2008 Silver Butte entered into a Letter of Intent for a share exchange with Blue Arch Coal Company, a Wyoming corporation ("Blue Arch"). Blue Arch Coal Company is a privately held corporation that currently owns options to acquire four state coal leases in the Powder River Basin of Wyoming. The leases are estimated to contain 148.3 million tons of proven sub-bituminous coal reserves.

Under the terms of the proposed share exchange, at closing, each of the approximately 220,500,000 then outstanding shares of Blue Ach will be exchanged for shares of Silver Butte on a one for one basis (i.e. one share of Silver Butte will be issued in exchange for one share of Blue Arch). Closing of the transaction is contingent upon completion of Due Diligence by each corporation and negotiation of a definitive Share Exchange Agreement which must be approved by the Board of Directors of Silver Butte and Blue Arch and by the shareholders of Blue Arch holding majority of the outstanding shares of Blue Arch Common Stock. The Share Exchange Agreement will contain, among other conditions, a requirement that prior to closing Blue Arch shall have obtained equity financing in the minimum amount of $3million. After closing of the transaction it is anticipated that there will be a 1:5 reverse split of the Silver Butte Common stock and that Silver Butte shall amend its Articles of Incorporation changing the name of the Corporation to Blue Arch Energy, Inc.

DELCATH SYSTEMS, INC. (NASD:DCTH) Up 4.35% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=DCTH

Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested with the drug melphalan in Phase III and Phase II clinical trials. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

Recent DCTH News:

June 24, 2008 - Delcath Expands Multi-Center Phase III Trial for Metastatic Melanoma

Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the University of Texas Medical Branch at Galveston (UTMB), part of the University of Texas System, has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high-dose delivery of the anti-cancer agent melphalan. UTMB is the sixth center in this multi-center study testing the Delcath System.

Delcath and UTMB have entered into a clinical research agreement to conduct the Phase III National Cancer Institute (NCI) led study. Orhan S. Ozkan, MD, Associate Professor of Radiology and Director of Vascular and Interventional Radiology, will serve as the Principal Investigator of the study. On joining this study, Dr. Ozkan commented, "We are excited about being a part of this clinical trial and being the first center to offer this treatment modality to patients in this region of the US. This treatment offers tremendous promise for patients suffering from metastatic melanoma in the liver, and we are pleased to be able to offer this option to our patients."

Over the past two months, Delcath Systems has added five cancer centers to this Phase III trial, which needs fewer than sixty additional patients to reach full enrollment. On the addition of UTMB to this study, Richard Taney, President and CEO of Delcath, stated, "We continue our efforts to make this treatment option available at leading cancer centers throughout the United States. Dr. Ozkan's participation will provide patients in the southwest region of the country access to this trial and provides an important treatment option for inoperable metastatic melanoma to the liver. The interest in PHP by the physicians treating this fatal condition continues to grow and we continue working to expand the geographic availability of our technology."

The Phase III Study

The Phase III study is designed to test Delcath's proprietary PHP System for the regional delivery of melphalan to the liver to treat patients with metastatic ocular and cutaneous melanoma who have unresectable tumors in the liver. The Delcath System is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while preventing entry of the drugs to the rest of the patient's circulation. This isolation limits toxicities that result from systemic chemotherapy treatments.

Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath System or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to "cross over" and receive treatment with the Delcath System. The Phase III study, which recently exceeded 33% enrollment, is expected to be completed in 2009, leading to an application to the US Food and Drug Administration (FDA) for commercial approval of the PHP System.

About the University of Texas Medical Branch at Galveston

UTMB is a major academic health center dedicated to improving lives through health sciences education, clinical care and biomedical research. The University has six hospitals in Galveston, 90 campus- and community-based clinics, and four schools: medical, nursing, allied health sciences, and a graduate school for biomedical sciences. UTMB is the lead institution for the Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases and is the site of the Galveston National Laboratory, one of only two national biocontainment laboratories. Last year UTMB had $156 million in research expenditures with $105 million in NIH funding. Major research and patient care initiatives include a cancer center, a transplant center, molecular cardiology, burns care, neurology and the neurosciences, infectious disease, and women's and children's health. The University is the seventh largest employer among those headquartered in the Houston/Galveston region with 12,000 employees and a $1.4 billion budget. For more information, please visit the UTMB website at http://www.utmb.edu/

TELECOMMUNICATION SYSTEMS, INC. (NASD: TSYS)
Up 2.97% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=TSYS

TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS) produces wireless data communications technology solutions that require proven high levels of reliability. TCS provides wireless and VoIP E9-1-1 network-based services, secure deployable communication systems, engineered satellite-based services, and commercial location applications, like traffic and navigation, using the precise location of a wireless device. Customers include leading wireless, cable MSOs, and VoIP carriers around the world, and agencies of the U.S. Departments of Defense, State, and Homeland Security. For more information, visit www.telecomsys.com.

Recent TSYS News:

June 24, 2008 - TCS Awarded Multi-Million Dollar Contract to Provide a Private Satellite Network in Afghanistan

TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS), a leading provider of mission-critical wireless communications, today announced that it has been awarded a three-year, $2.4 million contract to build and implement an IP-based private satellite network that will support U.S. Department of Defense (DoD) personnel in Afghanistan.

This network, scheduled to be fully operational by mid-July, will provide voice, video, and data services in remote areas that lack terrestrial service. TCS will provide 24x7 network management and monitoring to ensure the highest network availability for the end users. TCS has a proven performance record implementing networks of this type around the world. Previously, TCS has built networks to support government agencies in South West Asia, Africa and in South America, as well as the largest private VSAT network in the Asia Pacific region for a leading U.S. banking organization.

"It is an honor and a privilege for TCS to deploy a network that will be enjoyed for off-duty use by men and women in Afghanistan," said Michael Bristol, Senior Vice President of TCS' Government Solutions Group. "Providing the technology to communicate with their loved ones back home is crucial to maintaining good morale."

TCS' Government Solutions Group began with the company's founding in 1987 as a government systems integrator. Today it is a leading provider of fixed and deployable communication solutions for government customers and mobile operators requiring high reliability and security, including the U.S. Army, U.S. Air Force, U.S. Navy, Unified Combatant Commands, U.S. Department of State (DoS), U.S. Secret Service (USSS), and various U.S. intelligence agencies. As a result of its extensive R&D effort, TCS has developed a suite of products under the SwiftLink® brand, designed for highly reliable, "on-the-quick-halt and on-the-move" secure communications for the DoD and other federal agencies. TCS' deployable communications systems and fixed site earth stations enable communications to some of the world's most hostile and remote locations.